Method for producing low antigenic cells
By identifying and modifying specific HLA alleles in donor cells to produce low antigenicity cells using precise genome editing and HLA protein inducers, the method addresses immune rejection and off-target issues in allogeneic transplantation, achieving reduced rejection and maintained antigen presentation.
Patent Information
- Application Number
- JP2023109941
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2018-02-16
- Filing Date
- 2023-07-04
- Publication Date
- 2024-11-26
- Estimated Expiration
- 2039-02-15
AI Technical Summary
Current methods for producing low antigenicity cells for allogeneic transplantation face challenges in determining appropriate target sequences for genome editing due to high sequence homology among HLA genes and significant individual sequence variations, leading to immune rejection and potential off-target mutations.
A method involving determining specific HLA alleles in donor cells that are not present in the recipient, destroying or modifying these alleles to produce cells that do not express HLA proteins, and using HLA protein expression inducers to selectively recover low antigenicity cells, combined with genome editing techniques to ensure precise target sequence identification.
The method effectively reduces immune rejection and maintains antigen-presenting capability, minimizing off-target mutations and ensuring compatibility for allogeneic cell transplantation.
Smart Images

Figure 0007590015000059 
Figure 0007590015000060 
Figure 0007590015000061
Abstract
Description
[Technical field]
[0001] The present invention relates to a method for producing low antigenic cells. More specifically, the present invention relates to a method for producing low antigenic cells, a kit for detecting low antigenic cells, cells, gRNA, and a method for identifying a target base sequence. This application claims priority based on Japanese Patent Application No. 2018-026421 filed in Japan on February 16, 2018, the contents of which are incorporated herein by reference. [Background technology]
[0002] In the case of allogeneic transplantation, in which cells from a donor are transplanted into a recipient (patient) from another person, the transplanted cells are rejected due to an immune response.
[0003] The most important role in distinguishing between self and non-self cells is played by cell surface proteins called HLA (Human Leukocyte Antigen) or major histocompatibility complex (MHC).
[0004] HLA is classified into class I and class II. Class I HLA proteins are expressed in most types of cells in the body. Class I HLA proteins form heterodimers with β2-microglobulin (B2M) and are expressed on the cell surface, where they function to present peptides to CD8 positive cytotoxic T cells and induce their activation. The antigen peptides presented are endogenous and are often 8 to 10 amino acids long.
[0005] HLA class I is classified into six main genes: HLA-A, HLA-B, HLA-C, HLA-E, HLA-F, and HLA-G. In addition, numerous pseudogenes (HLA-H, HLA-J, HLA-K, HLA-L, HLA-P, HLA-T, HLA-U, HLA-V, HLA-W, HLA-X, HLA-Y, etc.) are also known. Among these, the three genes with the greatest inter-individual sequence diversity are HLA-A, HLA-B, and HLA-C, which play a major role in distinguishing self from non-self in transplantation immunity.
[0006] Class II HLA proteins are mainly expressed in immune cells such as macrophages, dendritic cells, activated T cells, and B cells. Class II HLA proteins form heterodimers of α and β chains and have the function of presenting peptides to CD4 helper T cells and inducing their activation. The antigen peptides they present are exogenous and often have a length of 15 to 24 amino acids.
[0007] HLA class II is classified as follows: HLA-DR (α chain: HLA-DRA, β chain: HLA-DRB), HLA-DQ (α chain: HLA-DQA1, β chain: HLA-DQB1), and HLA-DP (α chain: HLA-DPA1 or HLA-DPA2, β chain: HLA-DPB1 or HLA-DPB2). It is also known that there are many other pseudogenes (HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB).
[0008] Due to their sequence diversity, HLA genes are involved in self-nonself recognition at the cellular level. During allogeneic transplantation, HLA matching is extremely important to reduce immune rejection. For example, in hematopoietic stem cell transplantation, it is recommended to find a donor with a matched antigenicity for both HLA-A, HLA-B, HLA-C, and HLA-DR alleles, i.e., a total of eight alleles.
[0009] In addition, when looking at the results of kidney transplant survival rates, it has been reported that the higher the degree of HLA antigenic match, the significantly higher the survival rate.
[0010] On the other hand, there is also an immune system induced by the absence of HLA antigens on the cell surface. NK cells express multiple inhibitory receptors. For example, the composite receptor of CD94 and NKG2A, which recognizes HLA-E and suppresses the activity of NK cells, is known to induce the activation of NK cells and attack them when it finds cells without HLA-E. There is also a receptor family called KIR (Killer cell Immunoglobulin-like Receptor), which is classified into 2D and 3D depending on the number of extracellular domains, and L (long) and S (short) depending on the length of the intracellular domain. It is known that the 2DL1 receptor recognizes HLA-C2, the 2DL2 and 2DL3 receptors recognize HLA-C1, the 2DL4 receptor recognizes HLA-G, 3DL1 recognizes HLA-Bw4, and 3DL2 recognizes HLA-A3 or HLA-A11 to suppress the activity of NK cells. KIR has polymorphisms; for example, it has been reported that almost all Japanese people (more than 98%) have 2DL1, 2DL3, or 3DL4, but only about 15% have 2DL2.
[0011] Meanwhile, pluripotent stem cells such as iPS cells and ES cells have the pluripotency to differentiate into various cell types. Therefore, cell therapy and regenerative medicine, in which pluripotent stem cells are differentiated into various types of cells and then transplanted into patients, are attracting attention.
[0012] In fact, there have been reports of cases where ES cells were differentiated into nerve cells and transplanted into patients with bone marrow damage, and cases where iPS cells were differentiated into retinal pigment epithelial cells and transplanted into patients with age-related macular degeneration, etc. It has been reported that when transplanting such pluripotent stem cell-derived cells, it is important to match the HLA type of the transplanted cells with that of the patient.
[0013] However, since the establishment of pluripotent stem cells requires a great deal of cost and time, it is difficult to prepare cells with matching HLA types for each patient. As one of the means for solving this problem, for example, Patent Document 1 describes cells in which the B2M gene required for cell surface presentation of class I HLA proteins has been deleted.
[0014] In recent years, genome editing technology using CRISPR-Cas9 and guide RNA (gRNA) has made it possible to induce double-stranded DNA breaks (DSBs) in genomic DNA depending on the target base sequence of the gRNA, thereby deleting part of the genomic DNA, and to insert any DNA fragment by co-introducing a template DNA with a sequence partially homologous to the vicinity of the double-stranded DNA break induction site together with Cas9 and gRNA.
[0015] However, in genome editing technology, DSB induction is determined by a spacer sequence of about 20 bases and a PAM sequence of about 3 to 5 bases in the gRNA that recognizes and binds to the target sequence. Therefore, unless the gRNA sequence matches the sequence of the target site, efficient DSB induction is difficult.
[0016] In addition, when a base sequence very similar to that of the target site, for example a base sequence that differs by only one base, is present in a site other than the target site, there is a risk that DSBs will be mistakenly induced in sites other than the target site, resulting in the induction of undesired genome sequence mutations, known as off-target mutation risk. [Prior art documents] [Patent documents]
[0017] [Patent Document 1] International Publication No. 2012 / 145384 Summary of the Invention [Problem to be solved by the invention]
[0018] The cells described in Patent Document 1 lack the B2M gene, and therefore do not present class I HLA proteins on the cell surface. This is thought to suppress immune responses in allogeneic transplantation. However, if HLA proteins are not presented on the cell surface, the cells lose their antigen-presenting ability. If a cell loses its antigen-presenting ability, when a B2M-deficient cell is infected with a virus or becomes tumorous, it will be unable to present antigens derived from the virus or tumor, and may end up helping the virus and tumor grow. In addition, cells that do not present HLA proteins on the cell surface will be attacked by NK cells that recognize the "missing self."
[0019] Therefore, it is conceivable to selectively destroy only the HLA genes of interest using genome editing technology. However, there are multiple HLA genes, and the sequence homology between the HLA genes, including many pseudogenes, is high. On the other hand, even for the same HLA gene, there is a large degree of sequence diversity between individuals, so even if a target base sequence that matches a certain HLA gene sequence is identified, it is not necessarily usable in cells derived from another donor. For this reason, it is not easy to determine an appropriate target sequence for genome editing. In addition, with conventional genome editing technology, it was extremely time-consuming to find cells with the desired genome editing.
[0020] An object of the present invention is to provide a technique for producing low antigenic cells that have a reduced rejection reaction when allogeneically transplanted into a recipient. [Means for solving the problem]
[0021] The present invention includes the following aspects. [1] A method for producing low antigenic cells from donor cells that have a reduced rejection reaction when allogeneically transplanted into a recipient, the method comprising: determining the Human Leukocyte Antigen (HLA) alleles of the donor cells and the recipient, respectively; identifying an HLA allele that is present in the donor cells but not in the recipient; and destroying or modifying the identified HLA allele to obtain a cell population containing cells that do not express an HLA protein specific to the donor cells, wherein the cells that do not express an HLA protein specific to the donor cells are the low antigenic cells. [2] The manufacturing method described in [1], wherein the HLA alleles determined in determining the HLA alleles of the donor cell and the recipient, respectively, include HLA-A alleles, HLA-B alleles, and HLA-C alleles. [3] The manufacturing method according to [1] or [2], further comprising, after obtaining a cell population containing cells that do not express an HLA protein specific to the donor cells, recovering the cells that do not express an HLA protein specific to the donor cells from the cell population, wherein the recovering comprises contacting the cell population with an HLA protein expression inducer, and recovering the cells that do not express an HLA protein specific to the donor cells from the cell population using the expression of the HLA protein specific to the donor cells in the cell population contacted with the HLA protein expression inducer as an indicator. [4] The manufacturing method described in [3], wherein the HLA protein expression inducer is interferon (IFN)-γ, IFN-α, IFN-β, interleukin (IL)-4, Granulocyte Macrophage colony-stimulating Factor (GM-CSF), Transforming growth factor (TGF)-α or TGF-β. [5] The method according to any one of [1] to [4], wherein the low antigenic cells are pluripotent stem cells. [6] A kit for detecting low-antigenic cells that contain an HLA protein expression inducer and that reduce the risk of rejection when allogeneically transplanted into a recipient. [7] The kit described in [6], wherein the HLA protein expression inducer is IFN-γ, IFN-α, IFN-β, IL-4, GM-CSF, TGF-α or TGF-β. [8] The kit according to [6] or [7], wherein the low antigenic cells are pluripotent stem cells. [9] An HLA protein expression inducer consisting of IFN-γ, IFN-α, IFN-β, IL-4, GM-CSF, TGF-α or TGF-β.
[10] A cell in which at least one HLA allele has been destroyed or altered and which is capable of expressing at least one HLA protein.
[11] The cell described in
[10] , wherein the HLA allele includes an HLA-A allele, an HLA-B allele, or an HLA-C allele.
[12] The cell described in
[10] or
[11] , which is a low-antigenic cell that has a reduced rejection reaction when allogeneically transplanted into a recipient, and the destroyed or modified HLA allele is an HLA allele that is not present in the recipient.
[13] The cell according to any one of
[10] to
[12] , which is a pluripotent stem cell.
[14] The cell according to any one of
[10] to
[13] , wherein at least one allele selected from a Class II Major Histocompatibility Complex Transactivator (CIITA) allele, a Regulatory Factor X5 (RFX5) allele, a Regulatory Factor X Associated Protein (RFXAP) allele, and a Regulatory Factor X Associated Ankyrin Containing Protein (RFXANK) allele is further disrupted or modified.
[15] The cell according to any one of
[10] to
[14] , in which HLA-A alleles and HLA-B alleles are disrupted and which is capable of expressing at least one type of HLA-C protein.
[16] The cell described in
[15] , wherein the HLA-C protein is a protein encoded by one allele selected from the group consisting of HLA-C*01:02 allele, HLA-C*02:02 allele, HLA-C*03:03 allele, HLA-C*03:04 allele, HLA-C*04:01 allele, HLA-C*05:01 allele, HLA-C*06:02 allele, HLA-C*07:01 allele, HLA-C*07:02 allele, HLA-C*08:01 allele, HLA-C*12:02 allele, and HLA-C*16:01 allele.
[17] A method for producing low-antigenic cells from donor cells that have a reduced rejection reaction when allogeneically transplanted into a recipient, the method comprising destroying or modifying alleles of the donor cells, including at least one of the CIITA allele, RFX5 allele, RFXAP allele, and RFXANK allele, wherein the cells in which the CIITA allele, RFX5 allele, RFXAP allele, or RFXANK allele has been destroyed or modified are the low-antigenic cells.
[18] The cell described in
[17] , wherein the low antigenic cell is a pluripotent stem cell.
[19] A cell in which at least one of the CIITA allele, RFX5 allele, RFXAP allele, and RFXANK allele has been destroyed or modified.
[20] The cell described in
[19] , which is a pluripotent stem cell.
[21] A gRNA that targets a base sequence that maps to only one targeted HLA haplotype when mapped against the base sequence data of genomic DNA for all HLA haplotypes, but does not map when mapped against the base sequence data of all genomic DNA other than HLA alleles.
[22] The gRNA described in
[21] , wherein the target nucleotide sequence is a nucleotide sequence set forth in any one of SEQ ID NOs: 3, 4, 7, 45 to 52, and 72 to 2459, or a nucleotide sequence in which one or several nucleotides have been deleted, substituted, or added at the 5' end of the nucleotide sequence set forth in any one of SEQ ID NOs: 3, 4, 7, 45 to 52, and 72 to 2459.
[23] The gRNA according to
[21] or
[22] , wherein the target nucleotide sequence is a nucleotide sequence set forth in any one of SEQ ID NOs: 3, 4, 7, 45 to 52, or a nucleotide sequence in which one or several nucleotides have been deleted, substituted or added at the 5' end of the nucleotide sequence set forth in any one of SEQ ID NOs: 3, 4, 7, 45 to 52.
[24] The gRNA described in any one of
[21] to
[23] , wherein the target base sequence is mapped to exon 2 or 3 of the HLA gene.
[25] A gRNA whose target sequence is a nucleotide sequence that maps to two or more target HLA haplotypes when mapped against the nucleotide sequence data of the genomic DNA of all HLA haplotypes, but does not map when mapped against the nucleotide sequence data of all genomic DNA other than HLA alleles.
[26] The gRNA described in
[25] , wherein the target nucleotide sequence is a nucleotide sequence set forth in any one of SEQ ID NOs: 53 to 55, 2460 to 8013, or a nucleotide sequence in which one or several nucleotides have been deleted, substituted or added at the 5' end of the nucleotide sequence set forth in any one of SEQ ID NOs: 53 to 55, 2460 to 8013.
[27] The gRNA described in
[25] or
[26] , wherein the target base sequence is a base sequence set forth in any one of SEQ ID NOs: 53 to 55, or a base sequence in which one or several bases have been deleted, substituted or added at the 5' end of the base sequence set forth in any one of SEQ ID NOs: 53 to 55.
[28] The gRNA described in any one of
[25] to
[27] , wherein the target base sequence is mapped to exon 2 or 3 of the HLA gene.
[29] A method for identifying a target base sequence for producing low antigenic cells by genome editing that have reduced rejection when allogeneically transplanted into a recipient, the method comprising: mapping a candidate base sequence against base sequence data of genomic DNA of all HLA haplotypes; mapping the candidate base sequence against base sequence data of all genomic DNA other than HLA alleles; and identifying as a target base sequence the candidate base sequence that is mapped to only one target HLA haplotype when mapped against the base sequence data of genomic DNA of all HLA haplotypes, but is not mapped when mapped against the base sequence data of all genomic DNA other than HLA alleles.
[30] A method for identifying a target base sequence for producing low antigenic cells by genome editing that have a reduced rejection reaction when allogeneically transplanted into a recipient, the method comprising: mapping a candidate base sequence against base sequence data of genomic DNA of all HLA haplotypes; mapping the candidate base sequence against base sequence data of all genomic DNA other than HLA alleles; and identifying as a target base sequence the candidate base sequence that is mapped to two or more target HLA haplotypes when mapped against the base sequence data of genomic DNA of all HLA haplotypes but is not mapped when mapped against the base sequence data of all genomic DNA other than HLA alleles. Effect of the Invention
[0022] According to the present invention, a technique for producing low antigenic cells with reduced rejection reactions when allogeneically transplanted into a recipient can be provided. [Brief description of the drawings]
[0023] [Figure 1] (a) is a Venn diagram showing the HLA alleles targeted by the sgRNA extracted in Experimental Example 1. (b) is a diagram showing which of the HLA-A alleles, HLA-B alleles, and HLA-C alleles the sgRNA identified in Experimental Example 1 targets. [Diagram 2]1 is a graph showing the results of flow cytometry in Experimental Example 2. [Diagram 3] 1 is a graph showing the results of flow cytometry in Experimental Example 3. [Figure 4] 1(a) is a graph showing the results of flow cytometry in Experimental Example 4. FIG. 1(b) is a diagram showing a schedule for the analysis of IFN-γ treatment of iPS cells and the expression level of HLA-A protein in Experimental Example 4. [Diagram 5] 1A is a diagram showing the target site and target base of sgRNA in Experimental Example 6. FIG. 1B is a photograph showing the results of a T7 endonuclease I assay in Experimental Example 6. [Figure 6] 6(a) and (b) are graphs showing the results of flow cytometry in Experimental Example 7. [Figure 7] 13 is a graph showing the percentage of base sequence mutations in each clone in Experimental Example 7. [Figure 8] 6(a) and (b) are graphs showing the results of flow cytometry in Experimental Example 8. [Figure 9] 6(a) and (b) are graphs showing the results of flow cytometry in Experimental Example 8. [Figure 10] 1(a) shows the nucleotide mutation pattern of each clone recovered in Experimental Example 8. FIG. 1(b) shows the nucleotide sequence of a representative clone recovered in Experimental Example 8. [Figure 11] 13 is a graph showing the results of flow cytometry in Experimental Example 9. [Figure 12] FIG. 1(a) shows the nucleotide mutation pattern of each clone recovered in Experimental Example 9. FIG. 1(b) shows the nucleotide sequence of a representative clone recovered in Experimental Example 9. [Figure 13] 10(a) and 10(b) show the nucleotide mutation patterns of the clones recovered in Experimental Example 10. FIG. 10(c) shows the nucleotide sequence of a representative clone recovered in Experimental Example 10. [Figure 14]1(a) shows the nucleotide mutation pattern of each clone recovered in Experimental Example 11. FIG. 1(b) shows the nucleotide sequence of a representative clone recovered in Experimental Example 11. [Figure 15] FIG. 1(a) is a graph showing the results of flow cytometry in Experimental Example 11. FIG. 1(b) is a diagram showing the nucleotide mutation pattern of each clone recovered in Experimental Example 11. FIG. 1(c) is the nucleotide sequence of a representative clone recovered in Experimental Example 11. [Figure 16] 1A is a diagram showing target sites of sgRNA in Experimental Example 12. 1B and 1C are graphs showing the results of flow cytometry in Experimental Example 12. [Figure 17] 1(a) shows the nucleotide mutation pattern of the clone recovered in Experimental Example 12. FIG. 1(b) shows the nucleotide sequence of the clone recovered in Experimental Example 12. [Figure 18] FIG. 1(a) is a graph showing the results of flow cytometry in Experimental Example 13. FIG. 1(b) and FIG. 1(d) are diagrams showing the nucleotide mutation patterns of each clone recovered in Experimental Example 13. FIG. 1(c) and FIG. 1(e) are nucleotide sequences of representative clones recovered in Experimental Example 13. [Figure 19] (a) and (b) are graphs showing the results of flow cytometry in Experimental Example 14. (c) is a diagram showing the nucleotide mutation pattern of each clone recovered in Experimental Example 14. (d) is the nucleotide sequence of a representative clone recovered in Experimental Example 14. [Figure 20] 1A is a diagram showing target sites of sgRNA in Experimental Example 15. 1B and 1C are graphs showing the results of flow cytometry in Experimental Example 15. [Figure 21] 13(a) and (b) are schematic diagrams illustrating homologous recombination in Experimental Example 16. FIG. 13(c) is a graph showing the results of flow cytometry in Experimental Example 15. [Figure 22] 13(a) and (b) show the results of analysis of the base sequence in Experimental Example 16. [Diagram 23]13(a) and (b) are graphs showing the results of flow cytometry in Experimental Example 17. FIG. 13(c) is a diagram showing the results of base sequence analysis in Experimental Example 17. [Figure 24] 17(a) is a graph showing the results of flow cytometry in Experimental Example 18. FIG. 17(b) is a diagram showing the results of base sequence analysis in Experimental Example 18. [Diagram 25] Graphs (a) to (e) show the results of flow cytometry in Experimental Example 19. [Figure 26] Graphs (a) to (f) show the results of flow cytometry in Experimental Example 20. [Figure 27] Graphs (a) to (e) show the results of flow cytometry in Experimental Example 21. [Figure 28] FIG. 13 is a schematic diagram showing the procedure of Experimental Example 22. [Figure 29] Graphs (a) to (e) show the results of flow cytometry in Experimental Example 22. [Diagram 30] FIG. 13 is a schematic diagram showing the procedure of Experimental Example 23. [Diagram 31] 13 is a graph showing the results of Experimental Example 23. [Diagram 32] 13 is a graph showing the results of Experimental Example 24. [Diagram 33] 13 is a graph showing the results of Experimental Example 25. [Diagram 34] Graphs (a) and (b) show the results of flow cytometry in Experimental Example 26. Graph (c) shows the results of Experimental Example 26. [Diagram 35] Graphs (a) to (g) show the results of flow cytometry in Experimental Example 27. [Diagram 36] 13 is a graph showing the results of Experimental Example 28. [Figure 37] 6(a) to 6(f) are phase-contrast micrographs showing the results of Experimental Example 29. [Figure 38] 6(a) to 6(f) are phase contrast micrographs showing the results of Experimental Example 30. [Figure 39]Graphs (a) and (b) show the results of flow cytometry in Experimental Example 31. Graph (c) shows the results of Experimental Example 31. [Diagram 40] Graphs (a) and (b) show the results of flow cytometry in Experimental Example 32. Graph (c) shows the results of Experimental Example 32. [Diagram 41] FIG. 1(a) is a diagram explaining the experimental schedule in Experimental Example 33. FIG. 1(b) is a photograph showing the results of photographing the fluorescence of EB-derived blood cell-like cells in Experimental Example 33. FIG. 1(c) is a graph showing the survival rate of EB-derived blood cell-like cells in Experimental Example 33. [Diagram 42] 13(a) is a graph showing the results of flow cytometry analysis in Experimental Example 34; and (b) is a graph showing the results of Experimental Example 34. [Diagram 43] 13(a) is a graph showing the results of flow cytometry analysis in Experimental Example 35; and (b) is a graph showing the results of Experimental Example 35. [Diagram 44] Graphs (a) and (b) show the results of flow cytometry analysis in Experimental Example 36. [Diagram 45] FIG. 1(a) is a diagram explaining the experimental schedule in Experimental Example 37. FIG. 1(b) is a photograph showing the results of photographing the fluorescence of EB-derived blood cell-like cells in Experimental Example 37. FIG. 1(c) is a graph showing the relative survival rate of EB-derived blood cell-like cells in Experimental Example 37. [Diagram 46] 13 is a graph showing the results of Experimental Example 38. [Figure 47] 1(a) is a table showing the HLA haplotypes of the 585A1-C7 remaining cells used in Experimental Example 39, and the HLA haplotypes of the 585A1-C7 remaining cells in which the CIITA gene has been knocked out, produced in Experimental Example 39. FIG. 1(b) is a diagram showing the nucleotide mutation patterns of each clone obtained in Experimental Example 39. FIG. 1(c) is a nucleotide sequence of a representative clone obtained in Experimental Example 39. [Figure 48] 6(a) to (d) are graphs showing the results of flow cytometry in Experimental Example 40. [Figure 49] 6(a) to 6(c) are graphs showing the results of flow cytometry in Experimental Example 41. [Figure 50] 13(a) to 13(c) are diagrams illustrating the procedure of Experimental Example 42. [Figure 51] 2(a) is a graph showing the results of flow cytometry in Experimental Example 42. FIG. 2(b) is a diagram showing the nucleotide mutation patterns of each subclone obtained in Experimental Example 42. [Figure 52] 13(a) and (b) show the nucleotide mutation patterns of each subclone obtained in Experimental Example 42. [Diagram 53] 1 is a table showing the allele frequencies of HLC-C alleles in various races. [Figure 54] FIG. 13 shows the nucleotide mutation patterns of each subclone obtained in Experimental Example 43. [Figure 55] FIG. 13 shows the nucleotide mutation patterns of each subclone obtained in Experimental Example 44. [Figure 56] Graphs (a) and (b) show the results of flow cytometry in Experimental Example 45. [Figure 57] 1 is a graph showing the results of flow cytometry in Experimental Example 46. [Figure 58] FIG. 13 shows the nucleotide mutation patterns of each subclone obtained in Experimental Example 47. [Figure 59] FIG. 13 shows the nucleotide mutation patterns of each subclone obtained in Experimental Example 48. [Figure 60] FIG. 13 shows the nucleotide mutation patterns of each subclone obtained in Experimental Example 49. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0024] [Method for producing hypoantigenic cells with reduced rejection] (First embodiment) The manufacturing method of the first embodiment is a method for producing low-antigenic cells from donor cells that have a reduced rejection reaction when allogeneically transplanted into a recipient, the method comprising: (a) determining the HLA alleles of the donor cells and the recipient, respectively; (b) identifying an HLA allele that is present in the donor cells but not in the recipient; and (c) destroying or modifying the identified HLA allele to obtain a cell population containing cells that do not express an HLA protein specific to the donor cells, wherein the cells that do not express an HLA protein specific to the donor cells are the low-antigenic cells.
[0025] As described later in the Examples, the manufacturing method of the first embodiment makes it possible to manufacture low antigenic cells with reduced rejection (graft-versus-host disease) when allogeneically transplanted into a recipient. Furthermore, as described later in the Examples, the low antigenic cells manufactured by the manufacturing method of the first embodiment are less likely to be attacked by the recipient's NK cells when allogeneically transplanted into a recipient.
[0026] In this specification, the HLA locus is sometimes referred to as an “HLA allele,” and the antigen diversity of the HLA protein presented on the cell surface is sometimes referred to as an “HLA type.” Each step will be described below.
[0027] (Step (a)) In this step, the HLA alleles of the donor cell and the recipient are determined. The donor cell may be a human cell or a non-human animal cell. The donor cell may be a pluripotent stem cell or a differentiated cell. In this specification, the pluripotent stem cell means an embryonic stem cell (ES cell), an induced pluripotent stem cell (iPS cell), etc.
[0028] Furthermore, the low antigenic cells produced by the production method of the first embodiment are cells in which the HLA alleles of donor cells have been destroyed or modified. Therefore, the low antigenic cells may be pluripotent stem cells similar to the donor cells, or may be differentiated cells.
[0029] In addition, the recipient is preferably an animal of the same species as the low antigenic cells. The recipient may be an actual patient scheduled for transplantation, or may be a potential recipient having a hypothetical HLA allele.
[0030] The determination of HLA alleles can be performed by conventional methods such as PCR-rSSO (PCR-reverse sequence specific oligonucleoid), PCR-SSP (sequence specific primer), PCR-SBT (sequence based typing), and next-generation sequencing, using a commercially available HLA typing kit, etc. In addition, HLAreporter, HLA-PRG, hla-genotyper, PHLAT, Optitype, neXtype, Athlates, HLAforest, SOAP-HLA, HLAminer, seq2HLA, GATK HLA Caller, etc. are known as software for performing HLA typing from sequence data of next-generation sequencers such as whole genome sequencing (WGS), exome sequencing (WES), and RNA-seq.
[0031] The HLA alleles determined in this step are preferably HLA alleles highly associated with rejection reactions when cell transplantation is performed, and preferably include HLA-A alleles, HLA-B alleles, and HLA-C alleles.
[0032] The HLA alleles determined in this step may further include HLA-DR alleles, HLA-DQ alleles, and HLA-DP alleles, and may further include other HLA alleles.
[0033] (Step (b)) In this step, HLA alleles that are not present in the recipient but are present in the donor cells (hereinafter sometimes referred to as "donor-specific HLA alleles") are identified. Donor-specific HLA alleles can be identified by comparing the HLA alleles of the donor cells with the HLA alleles of the recipient.
[0034] HLA alleles are sequences of bases encoded on genomic DNA that code for HLA proteins. The serological classification of HLA proteins is called HLA antigen type. Methods for identifying HLA antigen types include analyzing reactivity with serum or antibodies that recognize specific HLA antigen types, and comparing the DNA of HLA alleles or the base sequence of RNA transcribed from HLA alleles with existing correspondence tables or the IPD-IMGT database (https: / / www.ebi.ac.uk / ipd / imgt / hla / ).
[0035] HLA antigen type generally refers to differences in the first region (two-digit notation) of the HLA allele notation (http: / / hla.alleles.org / nomenclature / naming.html); however, in this specification, even if the HLA antigen type is serologically the same, if the amino acid sequence is different (nonsynonymous substitution), it is determined to be a different HLA allele.
[0036] Specifically, the first and second regions (four-digit notation) of the HLA allele notation are used to determine whether they are the same HLA allele or different. HLA alleles whose first and second regions of the HLA allele notation match are determined to be the same HLA allele. In addition, when it is necessary to distinguish the base sequence of the genome, such as when determining the target sequence for genome editing, differences in the third region (base substitution within the translation region without amino acid mutation) and the fourth region (base substitution outside the translation region) may also be taken into consideration.
[0037] (Process (c)) When cells having HLA proteins of HLA antigen types not present in the recipient are allografted into the recipient, a rejection reaction occurs and the transplanted cells are rejected. Therefore, in this process, donor-specific HLA alleles are destroyed or modified to obtain a cell population containing cells that do not express HLA proteins specific to the donor cells (hereinafter sometimes referred to as "donor-specific HLA proteins").
[0038] Here, cells that do not express donor-specific HLA proteins are cells in which the expression of a specific HLA protein has become negative due to the destruction of the HLA allele of the donor cell, or cells in which the HLA allele of the donor cell has been altered to change from a specific HLA type to another HLA type.
[0039] The cells that do not express donor-specific HLA proteins obtained by this step are low antigenic cells. Note that, if there are no donor-specific HLA proteins, this step is not necessary.
[0040] It is preferable that the B2M gene is not destroyed in the low antigenic cells produced by the production method of the first embodiment. This allows class I HLA proteins to be presented on the cell surface, and even when the low antigenic cells are allogeneically transplanted into a recipient, they are less likely to be attacked by the recipient's NK cells. In addition, since only a portion of the HLA is destroyed and the remaining HLA retains the antigen-presenting ability, the antigen-presenting ability can be maintained even if the cells are infected with a virus or become tumorigenic.
[0041] Genome editing As described later in the Examples, the destruction or modification of the HLA allele of the donor cell can be performed, for example, by genome editing. The destruction of the HLA allele can be performed by specifically cutting the HLA allele to induce double-stranded DNA breaks (DSBs). When a base is deleted or added during the repair process of the DSB, resulting in a frameshift mutation, the HLA allele is destroyed and the HLA protein is not expressed. In this specification, the destruction of the HLA allele may be referred to as knocking out the HLA allele.
[0042] In addition, by specifically cleaving an HLA allele in the presence of donor DNA to induce DSB, homologous recombination can be induced during the DSB repair process to modify the HLA allele. Specifically, for example, as described below in the Examples, it is possible to modify the HLA-A*02:07 allele to the HLA-A*01:01 allele.
[0043] The donor DNA used should have sequence identity with the region including the region before and after the double-stranded DNA break in the genomic DNA and encode the desired HLA allele. The donor DNA may be single-stranded or double-stranded. The donor DNA may be a DNA having a single base sequence or a mixture of DNAs having multiple base sequences.
[0044] Here, having sequence identity means that 90% or more of the base sequence between the donor DNA and the region containing the site of double-stranded break in the target genomic DNA matches. The donor DNA preferably matches 95% or more of the base sequence with the region containing the site of double-stranded break in the genomic DNA, and more preferably matches 99% or more of the base sequence.
[0045] The donor DNA may be a single-stranded DNA of about 50 to 5,000 base pairs, or a double-stranded DNA of about 50 to 5,000 base pairs. When the donor DNA is a single-stranded DNA, the donor DNA may have sequence identity with either strand of the double strand of the genomic DNA.
[0046] <Sequence-specific DNA cleavage enzyme> In general, sequence-specific DNA cleavage enzymes used to induce DSBs and perform genome editing are roughly divided into RNA-guided nucleases and artificial nucleases. The sequence-specific DNA cleavage enzyme may be an RNA-guided nuclease or an artificial nuclease.
[0047] The sequence-specific DNA cleavage enzyme is not particularly limited as long as it specifically cleaves genomic DNA in a target sequence to form a double-stranded break. The length of the target sequence recognized by the sequence-specific DNA cleavage enzyme may be, for example, about 10 to 60 bases.
[0048] In addition, the sequence-specific DNA cleaving enzyme may be, for example, a combination of multiple nickases to cleave DNA. Here, nickase refers to an enzyme that forms a nick in one strand of a double-stranded DNA. For example, a double-stranded break can be formed by forming a nick in both strands of the double-stranded DNA at adjacent positions on the genomic DNA.
[0049] An RNA-guided nuclease is an enzyme in which a guide short-stranded RNA binds to a target sequence and recruits a nuclease having two DNA cleavage domains (nuclease domains) to induce sequence-specific cleavage. Examples of RNA-guided nucleases include CRISPR-Cas family proteins. CRISPR-Cas family proteins are broadly classified into class 1 and class 2, with class 1 including type I, type III, and type IV, and class 2 including type II, type V, and type VI.
[0050] Examples of CRISPR-Cas family proteins include Cas9, Cpf1, CasX, CasY, Cas12, Cas13, and C2C2. The RNA-guided nuclease may be a homologue of a CRISPR-Cas family protein, or may be a modified CRISPR-Cas family protein. For example, it may be a nickase-modified nuclease in which one of the two wild-type nuclease domains is modified to an inactive form. Alternatively, it may be Cas9-HF, HiFi-Cas9, eCas9, or the like, which has improved target specificity.
[0051] Examples of Cas9 include those derived from Streptococcus pyogenes, Staphylococcus aureus, Streptococcus thermophilus, Geobacillus stearothermophilus, etc. Examples of Cpf1 include those derived from Acidaminococcus, Lachnospira, Chlamydomonas, Francisella novicida, etc.
[0052] An artificial nuclease is an artificial restriction enzyme that has a DNA binding domain designed and produced to specifically bind to a target sequence and a nuclease domain (such as the DNA cleavage domain of the restriction enzyme FokI). Examples of artificial nucleases include, but are not limited to, zinc finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), meganucleases, and the like.
[0053] Introduction of sequence-specific DNA cleavage enzymes When using, for example, CRISPR-Cas as the sequence-specific DNA cleavage enzyme introduced into the donor cell, the target base sequence is determined by gRNA. Details of gRNA will be described later. gRNA may be introduced into the donor cell in the form of RNA, or may be introduced into the donor cell in the form of an expression vector and expressed in the cell.
[0054] Methods for preparing gRNA in the form of RNA include a method in which a construct is prepared by adding a promoter such as T7 upstream of a nucleic acid fragment encoding gRNA, and then synthesis is performed by in vitro transcription reaction, a method in which gRNA is chemically synthesized, etc. When chemically synthesizing gRNA, chemically modified RNA may be used.
[0055] Examples of the expression vector include a plasmid vector or a virus vector that transcribes gRNA from a Pol III promoter such as the H1 promoter or the U6 promoter. When expressing gRNA using an expression vector, gRNA may be expressed constitutively or under the control of an inducible promoter.
[0056] Next, Cas9 is prepared. Cas9 may be introduced into donor cells in the form of an expression vector expressed from a Pol II promoter, or in the form of a purified protein. Examples of expression vectors include transposon vectors, virus vectors, episomal vectors, and plasmid vectors.
[0057] When gRNA and Cas9 are in the form of a viral vector, they can be introduced into donor cells simply by adding them to the medium of the donor cells. Examples of viral vectors include adeno-associated virus vectors, adenovirus vectors, retrovirus vectors, lentivirus vectors, Sendai virus vectors, and baculovirus vectors.
[0058] When gRNA and Cas9 are transposon vectors, episomal vectors, plasmid vectors, etc., or when gRNA is RNA and Cas9 is a purified protein, they can be introduced into donor cells using a transfection reagent or electroporation method.
[0059] Examples of transfection reagents that can be used include Lipofectamine 2000, Lipofectamine 3000, CRISPRMAX, RNAMAX (all from Thermo Fisher Scientific), FuGENE 6, and FuGENE HD (all from Promega).
[0060] Furthermore, electroporation can be performed using equipment such as NEPA21 (Nepgene Co., Ltd.), Neon (Thermo Fisher Scientific), and 4D-Nucleofector (Lonza).
[0061] (Step (d)) In step (c), a cell population containing low antigenic cells that do not express donor-specific HLA proteins can be obtained. However, the cell population obtained in step (c) may contain cells in which the HLA alleles of interest have been destroyed or modified (low antigenic cells), as well as cells in which the HLA alleles have not been destroyed or modified, cells in which the HLA alleles have been incompletely destroyed or modified, etc. Therefore, after step (c), a step (d) of recovering cells that do not express donor-specific HLA proteins (low antigenic cells) may be further carried out.
[0062] Step (d) comprises the steps of contacting a cell population containing low antigenic cells with an HLA protein expression inducer (HLA protein expression inducer) and recovering cells that do not express the donor-specific HLA protein from the cell population using the expression of the donor-specific HLA protein in the cell population contacted with the HLA protein expression inducer as an indicator. The step of contacting the cell population with the HLA protein expression inducer can be carried out, for example, by adding the HLA protein expression inducer to the culture medium of the cell population.
[0063] In this step, recovering cells that do not express a donor-specific HLA protein from the cell population using the expression of a donor-specific HLA protein as an indicator may mean detecting the presence of an expressed HLA protein and recovering cells that do not express a donor-specific HLA protein based on the presence or absence.
[0064] Examples of HLA protein expression inducers include cytokines such as IFN-γ, IFN-α, IFN-β, IL-4, GM-CSF, TGF-α, TGF-β, etc. These expression inducers may be used alone or in combination of two or more.
[0065] When the above cytokines are used in human cells, they are preferably cytokines of human origin. The NCBI accession numbers for human IFN-γ protein are NP_000610.2, etc., the NCBI accession numbers for human IFN-α protein are NP_076918.1, NP_000596.2, NP_066546.1, etc., the NCBI accession numbers for human IFN-β protein are NP_002167.1, etc., and the NCBI accession numbers for human IL-4 protein are NP_000580.1, NP_758858.1, NP_000582.1, NP_000581.1, NP_000582.1, NP_000583.1, NP_000584.1, NP_000585.1, NP_000586.1, NP_000587.1, NP_000588.1, NP_000589.1, NP_000582.1, NP_000583.1, NP_000584.1, NP_000585.1, NP_000586.1, NP_000587 ... 001341919.1, etc., the NCBI accession number of the human GM-CSF protein is NP_000749.2, etc., the NCBI accession numbers of the human TGF-α protein are NP_001093161.1, NP_003227.1, NP_001295088.1, NP_001295087.1, etc., and the NCBI accession numbers of the human TGF-β protein are NP_000651.3, XP_011525544.1, etc.
[0066] The above cytokines may have a mutation in the amino acid sequence described in each of the above accession numbers, so long as they have the activity of inducing the expression of HLA proteins. More specifically, they may have an amino acid sequence in which one or several amino acids are deleted, substituted, or added to the amino acid sequence described in each of the above accession numbers. Here, one or several amino acids may be, for example, 1 to 10 amino acids, for example, 1 to 5 amino acids, for example, 1 to 3 amino acids. The above cytokines may further have an amino acid sequence in which a signal peptide has been removed.
[0067] It is known that pluripotent stem cells generally do not express HLA proteins on the cell surface in an undifferentiated state, making it difficult to detect HLA proteins. In order to present HLA proteins, differentiation induction is required. However, the differentiation induction process is generally complicated and time-consuming. In addition, once cells have been induced to differentiate, they do not spontaneously return to an undifferentiated state, so even if a population of differentiated cells negative for HLA proteins is collected, they are no longer pluripotent stem cells.
[0068] In response to this, the inventors have demonstrated that by applying the above-mentioned HLA protein expression inducer to pluripotent stem cells, it is possible to induce the expression of HLA proteins while maintaining the pluripotency of the pluripotent stem cells.
[0069] This enables induction of expression of HLA proteins in the cell population obtained in step (d), and efficient detection and recovery of pluripotent stem cells (low antigenic cells) in which the desired HLA allele has been destroyed or modified.
[0070] For example, after inducing the expression of an HLA protein in cells, the cells can be stained with an anti-HLA protein antibody, and HLA-expressing and non-expressing cells can be distinguished using a flow cytometer and recovered by sorting.
[0071] Alternatively, anti-HLA protein antibodies can be adsorbed onto magnetic beads and brought into contact with HLA protein-expressing cells, and the cells to which the magnetic beads are bound can be collected using magnetic force.
[0072] Alternatively, cells expressing a specific HLA protein on a culture dish can be labeled with an anti-HLA protein antibody or the like, and unnecessary non-target cells can be removed by suction or laser irradiation, and only the desired low antigenic cells can be collected.
[0073] Alternatively, HLA protein-expressing cells on a culture dish can be mixed with T cells that recognize an undesired HLA protein, and only the cells expressing the undesired HLA protein can be attacked and removed, allowing only the desired low-antigenic cells to be recovered.
[0074] The production method of the first embodiment may further include a step of disrupting or modifying at least one allele of the CIITA allele, the RFX5 allele, the RFXAP allele, and the RFXANK allele of the donor cell. The CIITA gene is a gene encoding a Class II Major Histocompatibility Complex Transactivator protein. The RFX5 gene is a gene encoding a Regulatory Factor X5 protein. The RFXAP gene is a gene encoding a Regulatory Factor X Associated Protein. The RFXANK gene is a gene encoding a Regulatory Factor X Associated Ankyrin Containing Protein.
[0075] The CIITA gene, together with the RFX5, RFXAP, and RFXANK genes, encodes a transcription factor that controls the transcriptional activation of HLA class II. Therefore, cells in which at least one of the CIITA, RFX5, RFXAP, and RFXANK alleles is destroyed do not express HLA class II proteins, and rejection is further reduced when transplanted into a recipient.
[0076] The NCBI accession numbers of the human CIITA gene are NM_000246.3, NM_001286402.1, NM_001286403.1, etc., the NCBI accession numbers of the human RFX5 gene are NM_000449.3, NM_001025603.1, etc., the NCBI accession numbers of the human RFXAP gene are NM_000538.3, etc., and the NCBI accession numbers of the human RFXANK gene are NM_001278727.1, NM_001278728.1, NM_003721.3, NM_134440.2, etc.
[0077] Second embodiment The manufacturing method of the second embodiment is a manufacturing method for manufacturing low antigenic cells from donor cells that have a reduced rejection reaction when allogeneically transplanted into a recipient, comprising destroying or modifying alleles including at least one of the CIITA allele, RFX5 allele, RFXAP allele, and RFXANK allele of the donor cells, and the low antigenic cells are cells in which the alleles including at least one of the CIITA allele, RFX5 allele, RFXAP allele, and RFXANK allele have been destroyed or modified. The manufacturing method of this embodiment differs mainly from the manufacturing method of the first embodiment described above in that it does not destroy HLA alleles.
[0078] As described above, the expression of the CIITA gene, the RFX5 gene, the RFXAP gene, and the RFXANK gene is known to be essential for the expression of HLA class II proteins. Therefore, cells in which at least one of the CIITA allele, the RFX5 allele, the RFXAP allele, and the RFXANK allele is destroyed do not express HLA class II proteins, and thus have a reduced rejection reaction when allogeneically transplanted into a recipient.
[0079] In the production method of the second embodiment, the donor cells may be pluripotent stem cells similar to those described above, or may be differentiated cells.
[0080] In addition, the recipient is preferably an animal of the same species as the low antigenic cells. The recipient may be an actual patient scheduled for transplantation, or may be a potential recipient having a hypothetical HLA allele.
[0081] As described above, the cells in which the B2M allele has been destroyed do not express HLA class I proteins even if the HLA allele is wild-type. The production method of the second embodiment may further include a step of destroying the B2M allele of the donor cell.
[0082] The CIITA allele or B2M allele of the donor cell can be destroyed by, for example, genome editing. The genome editing is similar to that described above.
[0083] [Kit for detecting low antigenic cells] In one embodiment, the present invention provides a kit for detecting low antigenic cells, which contains an HLA protein expression inducer and reduces the risk of rejection when allogeneically transplanted into a recipient. The kit of this embodiment can detect and recover low antigenic cells. Therefore, the kit of this embodiment can also be said to be a kit for recovering low antigenic cells.
[0084] In the kit of this embodiment, the HLA protein expression inducer is the same as that described above, and examples of the inducer include cytokines such as IFN-γ, IFN-α, IFN-β, IL-4, GM-CSF, TGF-α, TGF-β, etc. The kit of this embodiment may contain one of these expression inducers alone, or may contain two or more of them.
[0085] In the kit of this embodiment, the low antigenic cells may be pluripotent stem cells. As described later in the Examples, according to the kit of this embodiment, even when the low antigenic cells are pluripotent stem cells, it is possible to induce the expression of HLA proteins while maintaining the pluripotency of the low antigenic cells.
[0086] [cell] (First embodiment) The cell according to the first embodiment is a cell in which at least one HLA allele has been disrupted or modified and which is capable of expressing at least one type of HLA protein. The cell according to the first embodiment may be a pluripotent stem cell or a differentiated cell. In the cell according to the first embodiment, the at least one disrupted or modified HLA allele is preferably a class I HLA allele.
[0087] Pluripotent stem cells usually express HLA proteins weakly. Here, weak expression means that, for example, when cells are stained with an anti-HLA protein antibody and subjected to flow cytometry analysis, the expression of the HLA protein cannot be clearly detected.
[0088] However, as described later in the Examples, when pluripotent stem cells are contacted with an HLA protein expression inducer, the expression of HLA protein is enhanced. In the cell of the first embodiment, "capable of expressing at least one type of HLA protein" means that even if the cell is a cell that normally expresses HLA protein weakly, such as a pluripotent stem cell, the expression of HLA protein is enhanced by contacting the cell with, for example, the above-mentioned HLA protein expression inducer. The cell of the first embodiment may also be a cell that has differentiated and expressed HLA protein.
[0089] As described later in the Examples, for example, cells in which the B2M allele has been destroyed do not express HLA class I proteins even if the HLA allele is wild-type. The cells of the first embodiment do not include such cells.
[0090] In the cells of the first embodiment, the disrupted or modified HLA alleles preferably comprise class I HLA alleles, preferably HLA-A alleles, HLA-B alleles or HLA-C alleles.
[0091] The cells of the first embodiment express at least one type of class I HLA protein, and therefore are less likely to be attacked by the recipient's NK cells when allogeneically transplanted into the recipient. Examples of the at least one type of class I HLA protein include HLA-C protein, HLA-E protein, and HLA-G protein. The cells of the first embodiment have only a portion of the HLA destroyed, and the remaining HLA retains the antigen-presenting ability, so that the cells can maintain the antigen-presenting ability even when infected with a virus or tumorigenic.
[0092] The cells of the first embodiment are low-antigenic cells that have a reduced rejection reaction when allogeneically transplanted into a recipient, and the destroyed or modified HLA allele may be an HLA allele that is not present in the recipient. The low-antigenic cells have a reduced rejection reaction when allogeneically transplanted into a recipient.
[0093] The low antigenic cells of the first embodiment are preferably cells of the same species as the recipient, and may be human cells or non-human animal cells. The recipient may be an actual patient scheduled for transplantation, or a recipient having a hypothetical HLA allele who may become a future recipient.
[0094] The cells of the first embodiment may further have alleles including at least one of the CIITA allele, the RFX5 allele, the RFXAP allele, and the RFXANK allele disrupted or modified. As described above, it is known that the expression of the CIITA gene, the RFX5 gene, the RFXAP gene, and the RFXANK gene is essential for the expression of HLA class II proteins. Therefore, cells in which at least one of the CIITA allele, the RFX5 allele, the RFXAP allele, and the RFXANK allele is disrupted do not express HLA class II proteins, and the rejection reaction when allogeneically transplanted into a recipient is further reduced.
[0095] Second embodiment The cell according to the second embodiment is a cell in which alleles including at least one of the CIITA allele, the RFX5 allele, the RFXAP allele, and the RFXANK allele have been destroyed or modified. As described above, a cell in which alleles including at least one of the CIITA allele, the RFX5 allele, the RFXAP allele, and the RFXANK allele have been destroyed or modified is a low antigenic cell that does not express HLA class II protein and has a reduced rejection reaction when allogeneically transplanted into a recipient.
[0096] The cells according to the second embodiment may express HLA class I proteins. The cells according to the second embodiment may be useful for allogeneic transplantation into a recipient.
[0097] The cell of the second embodiment may be a pluripotent stem cell or a differentiated cell. As described above, the cell in which the B2M allele has been destroyed does not express HLA class I protein even if the HLA allele is wild type. The cell of the second embodiment may further have the B2M allele destroyed in addition to at least one of the CIITA allele, the RFX5 allele, the RFXAP allele, and the RFXANK allele.
[0098] The low antigenic cells of the second embodiment are preferably cells of the same species as the recipient, and may be human cells or non-human animal cells. The recipient may be an actual patient for whom transplantation is planned, or may be a potential recipient having a hypothetical HLA allele.
[0099] (Uses of low antigenic cells) The cells of the first and second embodiments described above are low antigenic cells that reduce the risk of rejection when allogeneically transplanted into a recipient, and can therefore be used in cell therapy and regenerative medicine.
[0100] When the low antigenic cells are pluripotent stem cells, they may be differentiated into, for example, nerve cells, liver cells, pancreatic islet cells, cardiomyocytes, kidney cells, hematopoietic stem cells, cytotoxic T cells, etc., and then transplanted into a patient.
[0101] Alternatively, genes may be introduced into low-antigenic cells and then transplanted into patients. For example, pluripotent stem cells may be differentiated into T cells, and then a chimeric antigen receptor (CAR) gene may be introduced into the T cells, followed by transplantation of the CAR-T cells into cancer patients.
[0102] [Method of identifying target base sequence] (First embodiment) In one embodiment, the present invention provides a method for identifying a target base sequence for producing, by genome editing, low antigenic cells with reduced rejection when allogeneically transplanted into a recipient, the method comprising: mapping a candidate base sequence to base sequence data of genomic DNA of all HLA haplotypes; mapping the candidate base sequence to base sequence data of all genomic DNA other than HLA alleles; and identifying, as a target base sequence, the candidate base sequence that is mapped to only one target HLA haplotype when mapped to the base sequence data of genomic DNA of all HLA haplotypes, but is not mapped when mapped to the base sequence data of all genomic DNA other than HLA alleles.
[0103] The method of the first embodiment allows the target base sequence of the gRNA of the first embodiment to be specified. As described below, the gRNA of the first embodiment can induce DSBs specifically for a particular HLA haplotype, and has a low risk of introducing off-target mutations.
[0104] As mentioned above, HLA genes have many pseudogenes, and the HLA gene sequences are highly homologous to each other, and there is a large degree of sequence diversity between individuals. For this reason, it is not easy to determine an appropriate target sequence for genome editing using sequence-specific DNA cleavage enzymes.
[0105] Identification of the target base sequence of the HLA gene-specific sequence-specific DNA cleavage enzyme can be performed, for example, as follows. First, the base sequence data of the genomic DNA of all HLA haplotypes (base sequence data of all known HLA genes) is obtained. The base sequence data of all HLA genes can be obtained, for example, from the IPD-IMGT / HLA database (https: / / www.ebi.ac.uk / ipd / imgt / hla / ). As of July 2017, this database contains 12,544 base sequences of HLA class I genes and 4,622 base sequences of HLA class II genes.
[0106] Next, from the base sequence of each HLA allele, a base sequence that is the target of the sequence-specific DNA cleavage enzyme to be used is extracted. For example, when CRISPR-Cas is used as the sequence-specific DNA cleavage enzyme, a base sequence that can be used as a target base sequence of gRNA, including a PAM sequence of about 3 to 5 bases (for example, "NGG" for Cas9 derived from Streptococcus pyogenes, and "TTTN" for Cpf1 derived from Acidaminococcus), is extracted and used as a candidate base sequence.
[0107] In the method of this embodiment, the target base sequence contains a PAM sequence. The length of the target base sequence containing a PAM sequence varies depending on the sequence-specific DNA cleavage enzyme. For example, when the sequence-specific DNA cleavage enzyme is Cas9 derived from Streptococcus pyogenes, the length of the target base sequence containing a PAM sequence is preferably 19 to 33 bases, more preferably 20 to 24 bases. When the sequence-specific DNA cleavage enzyme is Cpf1 derived from Acidaminococcus, the length of the target base sequence containing a PAM sequence is preferably 20 to 34 bases, more preferably about 24 bases.
[0108] Next, candidate base sequences containing the PAM sequence are mapped against the base sequence data of genomic DNA of all HLA haplotypes.
[0109] Mapping is an operation for identifying positions on a reference base sequence (here meaning base sequence data of genomic DNA of all HLA haplotypes) where the query base sequence (here meaning candidate base sequence) has high sequence identity. The sequence identity between the query base sequence and the reference base sequence is preferably 90% or more, more preferably 95% or more, even more preferably 99% or more, and particularly preferably 100%.
[0110] Here, the sequence identity of the query base sequence to the reference base sequence can be calculated, for example, as follows: First, the reference base sequence and the query base sequence are aligned. Then, the number of matching bases in the reference base sequence and the query base sequence is calculated, and the sequence identity can be calculated according to the following formula (1). Sequence identity (%) = number of matched bases / total number of bases in query sequence × 100 (1)
[0111] As described later in the Examples, mapping can be performed, for example, using the Bowtie program (http: / / bowtie-bio.sourceforge.net / index.shtml). Mapping may also be performed using sequence homology (sequence identity) search programs other than the Bowtie program, such as BWA, BLAST, BLAT, SOAP, Novoalign, TopHat, etc.
[0112] Next, the candidate base sequence is mapped to the base sequence data of the entire genomic DNA other than the HLA allele. As the base sequence data of the entire genomic DNA, the reference human genome sequence (Hg19) or the like can be used. For the mapping, the Bowtie program or a sequence homology search program other than the Bowtie program can be used.
[0113] Next, a candidate base sequence that is mapped to only one target HLA haplotype when mapped to the base sequence data of genomic DNA of all HLA haplotypes and is not mapped to the base sequence data of all genomic DNA other than HLA alleles is specified as a target base sequence. Here, the target HLA haplotype means the HLA haplotype to be disrupted or modified.
[0114] As described later in the Examples, a gRNA having a target base sequence identified by the method of the first embodiment as a target base sequence (gRNA of the first embodiment described later) can induce DSBs specifically to a particular targeted HLA haplotype, and also has a low risk of introducing off-target mutations.
[0115] Although the HLA gene is often composed of eight exons, the target nucleotide sequence preferably targets the protein coding region of the HLA gene, and more preferably targets exon 1, 2, 3 or 4, which codes for the extracellular domain of the HLA protein, and particularly preferably targets exon 2 or 3.
[0116] Alternatively, by setting two target base sequences, it is possible to delete a large portion of the base sequence between them. To utilize this, two or more target base sequences may be designed to include the gene region that codes for the protein of the HLA gene.
[0117] In addition, it is preferable that the target base sequence does not target other genomic regions or mitochondrial DNA other than the HLA genes. Even if a mismatch of several bases is allowed, it is preferable to select a target base sequence that has few sites that target regions other than the HLA genes.
[0118] Second embodiment In one embodiment, the present invention provides a method for identifying a target base sequence for producing low antigenic cells by genome editing that have a reduced rejection reaction when allogeneically transplanted into a recipient, the method comprising: mapping a candidate base sequence to base sequence data of genomic DNA of all HLA haplotypes; mapping the candidate base sequence to base sequence data of all genomic DNA other than HLA alleles; and identifying, as a target base sequence, the candidate base sequence that is mapped to two or more target HLA haplotypes when mapped to the base sequence data of genomic DNA of all HLA haplotypes but is not mapped when mapped to the base sequence data of all genomic DNA other than HLA alleles.
[0119] The method of the second embodiment differs from the method of the first embodiment described above mainly in that candidate base sequences that map to two or more target HLA haplotypes when mapped against base sequence data of genomic DNA of all HLA haplotypes are identified as target base sequences.
[0120] In the method of the second embodiment, the candidate base sequences, the base sequence data of genomic DNA of all HLA haplotypes, the base sequence data of all genomic DNA, and mapping are similar to those in the method of the first embodiment described above.
[0121] The method of this embodiment allows the identification of the target base sequence of the gRNA of the second embodiment described later. As described later, the gRNA of the second embodiment can cleave multiple target HLA genes (or alleles). This allows the number of types of gRNA required to destroy or modify multiple HLA genes to be reduced. This allows the cost of producing gRNA to be reduced. Furthermore, by reducing the number of types of gRNA used, the risk of introducing off-target mutations can also be reduced.
[0122] [gRNA] (First embodiment) In one embodiment, the present invention provides a gRNA whose target base sequence is a base sequence that is mapped to only one targeted HLA haplotype when mapped against base sequence data of genomic DNA of all HLA haplotypes, but is not mapped when mapped against base sequence data of all genomic DNA other than HLA alleles.
[0123] The gRNA of the first embodiment can induce DSBs specifically for a particular HLA haplotype, and has a low risk of introducing off-target mutations.
[0124] In this embodiment, the gRNA may be a complex of CRISPR RNA (crRNA) and transactivating CRISPR RNA (tracrRNA), or a single synthetic gRNA (sgRNA) that combines tracrRNA and crRNA. Either structure of the gRNA can induce DSB specifically in the target base sequence.
[0125] The target base sequence is preferably one specified by the above-mentioned method. As described above, in this specification, the target base sequence is a base sequence containing a PAM sequence. Therefore, the base sequence obtained by removing the PAM sequence from the target base sequence is used as the spacer base sequence of the crRNA or sgRNA.
[0126] When the gRNA of this embodiment is an sgRNA, the base sequence of the sgRNA can be the following base sequence.
[0127] First, the base sequence obtained by removing the PAM sequence from the target base sequence is designated as a spacer base sequence. Then, a base sequence is designed in which a scaffold sequence is linked to the 3' end of the spacer base sequence. As the scaffold sequence, for example, the base sequence shown in SEQ ID NO: 39 can be used, but is not limited thereto.
[0128] As long as the base sequence shown in SEQ ID NO: 39 functions as a scaffold sequence, it may be a base sequence in which one or several bases are deleted, substituted or added in the base sequence shown in SEQ ID NO: 39. Here, one or several bases may be, for example, 1 to 10 bases, for example, 1 to 5 bases, for example, 1 to 3 bases.
[0129] The designed sgRNA can be prepared by chemical synthesis, etc. The sgRNA may be prepared as RNA and directly introduced into the donor cell, or may be prepared as DNA and incorporated into an expression vector, which is then introduced into the donor cell in the form of the expression vector and expressed in the cell.
[0130] When expressing sgRNA in cells, a polymerase III promoter such as a U6 promoter or an H1 promoter can be used. In this case, the base sequence at the 5' end of the sgRNA may be changed to G or GG to improve transcription efficiency. Changing the base sequence at the 5' end of the sgRNA to G or GG has almost no effect on the cleavage activity of Cas9.
[0131] For example, if the base sequence obtained by removing the PAM sequence from the target base sequence is "5'-NNNNNNNNNNNNNNNNNNNN-3'" (sequence number 62), the base sequence of the sgRNA that specifically cleaves the target base sequence can be "5'-NNNNNNNNNNNNNNNNNNNNGUUUUAGAGCUAGAAAUAGCAAGUUAAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGCUUUUUUU-3'" (sequence number 63).
[0132] The gRNA of this embodiment may be a complex of crRNA and tracrRNA. In addition, the crRNA and tracrRNA may be directly introduced into the donor cell, or may be introduced into the donor cell in the form of an expression vector and expressed in the cell. When expressing the crRNA and tracrRNA in the cell, a polymerase III promoter such as a U6 promoter or an H1 promoter can be used. In this case, the base sequence at the 5' end of the crRNA or tracrRNA may be changed to G or GG in order to improve the transcription efficiency. Even if the base sequence at the 5' end of the crRNA or tracrRNA is changed to G or GG, the cleavage activity of Cas9 is hardly affected.
[0133] When the gRNA of this embodiment is a complex of crRNA and tracrRNA, the base sequences of the crRNA and tracrRNA can be the following base sequences.
[0134] First, the base sequence obtained by removing the PAM sequence from the target base sequence is designated as the spacer base sequence. Then, a base sequence in which a scaffold sequence is linked to the 3' end of the spacer base sequence is designed and designated as the base sequence of the crRNA. For example, when the base sequence obtained by removing the PAM sequence from the target base sequence is "5'-NNNNNNNNNNNNNNNNNNNN-3'" (SEQ ID NO: 62), the base sequence of the crRNA can be "5'-NNNNNNNNNNNNNNNNNNNNGUUUUAGAGCUAUGCUGUUUUG-3'" (SEQ ID NO: 64). In addition, the base sequence of the tracrRNA can be, for example, "5'-CAAAACAGCAUAGCAAGUUAAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGC-3'" (SEQ ID NO: 65).
[0135] The base sequence of the crRNA may have a mutation with respect to the base sequence set forth in SEQ ID NO: 64, so long as it functions as a crRNA. More specifically, the base sequence may be a base sequence in which one or several bases are deleted, substituted, or added in the base sequence set forth in SEQ ID NO: 64. Here, one or several bases may be, for example, 1 to 10 bases, for example, 1 to 5 bases, for example, 1 to 3 bases.
[0136] In addition, the base sequence of tracrRNA may be a base sequence in which one or several bases are deleted, substituted or added in the base sequence of SEQ ID NO: 65, so long as it functions as tracrRNA. Here, one or several bases may be, for example, 1 to 10 bases, for example, 1 to 5 bases, for example, 1 to 3 bases.
[0137] The designed crRNA and tracrRNA can be prepared by chemical synthesis, etc. The crRNA and tracrRNA may be prepared as RNA and directly introduced into donor cells, or may be prepared as DNA and incorporated into an expression vector, which is then introduced into donor cells in the form of the expression vector and expressed in the cells.
[0138] A specific example of the gRNA of the first embodiment is a gRNA having a target base sequence of any one of SEQ ID NOs: 3, 4, 7, 45-52, and 72-2459, or a gRNA having a target base sequence of any one of SEQ ID NOs: 3, 4, 7, 45-52, and 72-2459 in which one or several bases have been deleted, substituted, or added at the 5' end. Here, one or several bases may be, for example, 1 to 10 bases, for example, 1 to 5 bases, for example, 1 to 3 bases. For example, shortening the 5' end of the spacer sequence by 2 to 3 bases can reduce the binding ability to DNA and increase the sequence recognition specificity of CRISPR-Cas9.
[0139] Among them, gRNAs having as their target base sequence any one of the base sequences set forth in SEQ ID NOs: 3, 4, 7, 45 to 52, or gRNAs having as their target base sequence any one of the base sequences set forth in SEQ ID NOs: 3, 4, 7, 45 to 52 in which one or several bases have been deleted, substituted or added at the 5'-end thereof, are preferred. As described later in the Examples, gRNAs having these base sequences as their target base sequences can destroy or modify HLA alleles in an HLA haplotype-specific manner, thereby producing low antigenic cells with reduced rejection when allogeneically transplanted into a recipient.
[0140] Second embodiment In one embodiment, the present invention provides a gRNA whose target base sequence is a base sequence that is mapped to two or more target HLA haplotypes when mapped against base sequence data of genomic DNA of all HLA haplotypes, but is not mapped when mapped against base sequence data of all genomic DNA other than HLA alleles.
[0141] Specific examples of gRNAs according to the second embodiment include gRNAs having a target base sequence of any one of SEQ ID NOs: 53 to 55 and 2460 to 8013, or gRNAs having a target base sequence of any one of SEQ ID NOs: 53 to 55 and 2460 to 8013 in which one or several bases have been deleted, substituted or added at the 5' end. Here, one or several bases may be, for example, 1 to 10 bases, for example, 1 to 5 bases, for example, 1 to 3 bases. For example, shortening the 5' end of the spacer sequence by 2 to 3 bases can reduce the binding ability to DNA and increase the sequence recognition specificity of CRISPR-Cas9.
[0142] Among these, gRNAs having a target base sequence of any one of SEQ ID NOs: 53 to 55, or gRNAs having a target base sequence of any one of SEQ ID NOs: 53 to 55 in which one or several bases have been deleted, substituted or added at the 5' end, are preferred.
[0143] Furthermore, as described above, the base sequence at the 5' end of the gRNA may be changed to G or GG in order to improve the transcription efficiency from the polymerase III promoter.
[0144] For example, when focusing on HLA-A alleles, there are two HLA-A genes, one from the father and one from the mother, and the HLA-A genes may be different or the same. If you want to maintain the antigen presentation ability of HLA-A, you need to induce knockout by cutting only one HLA-A gene, leaving the opposite HLA-A gene intact. Alternatively, if you want to induce a complete knockout, you need to cut both HLA-A genes.
[0145] Generally, when targeting two genes with CRISPR-gRNA, two gRNAs are designed to induce DNA cleavage separately. Therefore, when knocking out multiple HLA genes, it is considered to use gRNAs specific to each HLA gene.
[0146] In response to this, as described later in the Examples, the inventors took advantage of the characteristic that HLA genes have high DNA sequence homology with each other and searched for a gRNA capable of inducing the cleavage of multiple HLA genes (e.g., both the paternally derived and maternal sequences of the HLA-A gene, or the HLA-A gene and the HLA-B gene) with a single gRNA, and were able to identify multiple such gRNA sequences.
[0147] As described later in the Examples, by using the gRNA of the second embodiment, the number of types of gRNA required for cleaving multiple HLA genes (or alleles) can be reduced. This can reduce the cost of producing gRNA. In addition, by reducing the number of types of gRNA used, the risk of introducing off-target mutations can also be reduced.
[0148] [Other embodiments] In one embodiment, the present invention provides an HLA protein expression inducer that contains IFN-γ, IFN-α, IFN-β, IL-4, GM-CSF, TGF-α or TGF-β as an active ingredient, and induces the expression of HLA protein while maintaining the pluripotency of pluripotent stem cells.
[0149] In one embodiment, the present invention provides a method for inducing expression of an HLA protein while maintaining the pluripotency of pluripotent stem cells, the method comprising the step of adding IFN-γ, IFN-α, IFN-β, IL-4, GM-CSF, TGF-α or TGF-β to the culture medium of the pluripotent stem cells. EXAMPLES
[0150] The present invention will now be described in more detail with reference to examples, but the present invention is not limited to the following examples.
[0151] [Experimental Example 1] (gRNA design) Because the sequences of HLA genes vary widely among individuals and are highly homologous to each other, it has been difficult to design a gRNA sequence that cleaves only a specific HLA haplotype. Specifically, it has been difficult to design a gRNA sequence that recognizes only the HLA-A*01:01 allele and does not recognize other HLA-A alleles, HLA genes other than HLA-A, or other genomic regions.
[0152] Therefore, the target sequences of gRNAs that recognize HLA-A, HLA-B, and HLA-C alleles were determined by the following method: First, the “hla_gen.fasta” file, which contains the genomic DNA sequences of all HLA haplotypes, was downloaded from the IPD-IMGT / HLA database (https: / / www.ebi.ac.uk / ipd / imgt / hla / ).
[0153] Next, from the base sequences of the genomic DNA of all HLA haplotypes, base sequences matching "NNNNNNNNNNNNNNNNNNNNNGG" (sequence number 40) were extracted as candidates for target base sequences of SpCas9 gRNA (sgRNA).
[0154] Next, the base sequence of each candidate was mapped to the base sequences of all HLA haplotypes using the Bowtie program (http: / / bowtie-bio.sourceforge.net / index.shtml), and the number of positions to which each candidate base sequence maps to each HLA gene was analyzed. Note that the same operation can also be performed using a sequence homology search program other than the Bowtie program.
[0155] Next, based on the results of the Bowtie program, each sgRNA was classified into cases where it binds to only one of the HLA-A alleles, HLA-B alleles, or HLA-C alleles, and cases where it binds to two or more HLA alleles, such as HLA-A alleles and HLA-B alleles, HLA-A alleles and HLA-C alleles, HLA-B alleles and HLA-C alleles, or HLA-A alleles, HLA-B alleles and HLA-C alleles.
[0156] Next, all the candidate sequences were mapped to the reference human genome sequence (Hg19) using Bowtie to confirm whether they mapped to genomic regions other than HLA alleles. As a result, the candidate sequences that mapped only to HLA alleles were extracted as the target sequences.
[0157] FIG. 1(a) is a Venn diagram showing which of the HLA-A allele, HLA-B allele, and HLA-C allele the target nucleotide sequence extracted in this experimental example targets. The numbers in the diagram indicate the number of target nucleotide sequences of the sgRNA. As a result, it was possible to determine a large number of target nucleotide sequences of sgRNAs that target only one of the HLA-A allele, HLA-B allele, or HLA-C allele, as well as target nucleotide sequences of sgRNAs that target two or more HLA alleles, such as HLA-A allele and HLA-B allele, HLA-A allele and HLA-C allele, HLA-B allele and HLA-C allele, HLA-A allele, HLA-B allele and HLA-C allele, and HLA-A allele, HLA-B allele and HLA-C allele.
[0158] Figure 1(b) shows which locations of the HLA-A allele, HLA-B allele, and HLA-C allele are targeted by the target base sequence of the sgRNA identified in this experimental example. In Figure 1(b), the boxes connected by lines indicate the exons of each HLA gene, with exon 1 on the left side for the HLA-A allele and exon 1 on the right side for the HLA-B allele and HLA-C allele. In addition, "[+]strand sgRNAs" indicates target base sequences that target plus-strand DNA, "[-]strand sgRNAs" indicates target base sequences that target minus-strand DNA, and "Unique k-mers" indicates a collection of 10-16mer base sequences (referred to as "k-mer sequences") that exist only once in the human genome.
[0159] As a result, it was revealed that a large number of sgRNA target sequences were found at the sites with high peaks of unique k-mers. Furthermore, a considerable number of target sequences were found in both the plus-strand DNA and the minus-strand DNA.
[0160] SEQ ID NOs: 3, 4, 7, 45-52, and 72-2459 show base sequences extracted as base sequences that are mapped to only one target HLA haplotype when mapped to base sequence data of genomic DNA of all HLA haplotypes, and are not mapped when mapped to base sequence data of all genomic DNA other than HLA alleles. In addition, the following Table 1 shows, as an example, the number of target HLA alleles and the target HLA alleles for some base sequences.
[0161] [Table 1]
[0162] SEQ ID NOs: 53 to 55 and 2460 to 8013 show base sequences extracted as base sequences that are mapped to two or more target HLA haplotypes when mapped to base sequence data of genomic DNA of all HLA haplotypes, and are not mapped when mapped to base sequence data of all genomic DNA other than HLA alleles. Table 2 below shows, as an example, the number of target HLA alleles and the target HLA alleles for some base sequences.
[0163] [Table 2]
[0164] Table 3 below shows the number of targeted HLA alleles and the number of extracted target base sequences for target base sequences that are mapped to two or more target HLA haplotypes when mapped against base sequence data of genomic DNA of all HLA haplotypes, but are not mapped when mapped against base sequence data of all genomic DNA other than HLA alleles.
[0165] [Table 3]
[0166] [Experimental Example 2] (Induction of HLA protein expression by stimulation of iPS cells 1) We attempted to stimulate undifferentiated iPS cells to induce the expression of HLA proteins. Specifically, we added 100ng / mL lipopolysaccharide (LPS), 100ng / mL TNF-α, or 50ng / mL IFN-γ to the iPS cell culture medium for 48 hours, and then performed flow cytometry analysis using an anti-HLA-ABC antibody (product number: 311418, BIOLEGEND) to examine the expression of HLA proteins.
[0167] Figure 2 is a graph showing the results of flow cytometry, which revealed that the addition of IFN-γ increased the expression of HLA proteins.
[0168] [Experimental Example 3] (Induction of HLA protein expression by stimulation of iPS cells 2) After adding 10 ng / mL, 50 ng / mL, or 100 ng / mL of IFN-γ to the iPS cell culture medium for 48 hours, flow cytometry analysis was performed using an anti-HLA-ABC antibody (product number: 311418, BIOLEGEND) to examine the expression of HLA proteins.
[0169] Figure 3 is a graph showing the results of flow cytometry. As a result, it was revealed that the expression of HLA proteins increased when IFN-γ was added. As a result, it was revealed that the expression of HLA proteins increased when IFN-γ was added at any concentration.
[0170] [Experimental Example 4] (Induction of HLA protein expression by stimulation of iPS cells 3) 50 ng / mL IFN-γ was added to the culture medium of iPS cells, and the cells were treated for 4, 8, 16, 24, and 48 hours. After that, flow cytometry analysis was performed using an anti-HLA-A2 antibody (product number: 740082, BD) to examine the expression of HLA-A2 protein.
[0171] FIG. 4(a) is a graph showing the results of flow cytometry. FIG. 4(b) is a diagram showing the schedule of IFN-γ treatment of iPS cells and analysis of the expression level of HLA-A protein. As a result, it was revealed that the longer the IFN-γ treatment time, the higher the expression of HLA protein. Furthermore, as a result of further investigation, it was revealed that the expression of HLA protein continued even 7 days after IFN-γ was removed from the medium after treating iPS cells with IFN-γ for 48 hours.
[0172] [Experimental Example 5] (Determination of HLA haplotype of cells) The HLA haplotype (pair of HLA alleles inherited from both parents) of each cell was determined by the following method.
[0173] For 604B1 iPS cells and 1383D2 iPS cells, first, FASTQ sequence files were created based on the results of WES (Whole Exome Sequencing) analysis of 604B1 iPS cells and WGS (Whole Genome Sequencing) analysis of 1383D2 iPS cells, respectively.
[0174] Each FASTQ sequence file was then mapped to the reference human genome sequence (Hg19) to generate a BAM file, and the HLA haplotype of each cell was determined by analyzing each BAM file using software (named "HLA-genotyper"; https: / / pypi.python.org / pypi / hla-genotyper / 0.4.2b1).
[0175] For the 585A1 iPS cells, the extracted genomic DNA was sent to the HLA Research Institute (http: / / hla.or.jp / ) and HLA haplotype determination was performed using the fluorescent bead method (PCR-rSSO / Luminex method). For the 604B1 iPS cells, the HLA haplotype determination was also performed in the same manner as for the 585A1 iPS cells.
[0176] In addition, peripheral blood mononuclear cells (PBMCs) for which HLA haplotype information was provided by the vendors (CTL, Wako) were used.
[0177] [Experimental Example 6] (Examination of genome cleavage activity of sgRNA) Among the sgRNAs targeting the target base sequences identified in Experimental Example 1, A0207-ex3-g1 (target base sequence shown in SEQ ID NO: 3), A0207-ex3-g2 (target base sequence shown in SEQ ID NO: 4), and A0207-ex3-g4 (target base sequence shown in SEQ ID NO: 7) were selected, which are sgRNAs that cleave only the A*02:07 allele and have a base sequence that does not match the A*32:01 allele.
[0178] The base sequence of each sgRNA used in each of the following experimental examples was a base sequence in which the scaffold sequence described in SEQ ID NO: 39 was linked to the 3' side of the base sequence obtained by removing the PAM sequence from the target base sequence of each sgRNA. For example, when the base sequence obtained by removing the PAM sequence from the target base sequence was "5'-NNNNNNNNNNNNNNNNNNNN-3'" (SEQ ID NO: 62), the base sequence of the sgRNA used was "5'-NNNNNNNNNNNNNNNNNNNNGUUUUAGAGCUAGAAAUAGCAAGUUAAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGCUUUUUUU-3'" (SEQ ID NO: 63). In each of the following experimental examples, each sgRNA was introduced into a cell in the form of an expression vector and expressed in the cell for use.
[0179] FIG. 5(a) shows the target site and target base of sgRNA found in the region of exon 3 of HLA-A. In FIG. 5(a), the boxes indicate the exons of the HLA-A*02:07 gene, and the arrows indicate the position of the target base sequence of each sgRNA. FIG. 5(a) also shows the base sequence of the wild-type A*02:07 allele and the wild-type A*32:01 allele. The parts where the sequences differ between the two alleles are shown in capital letters, and the PAM sequence of the sgRNA is underlined.
[0180] Next, A0207-ex3-g1, A0207-ex3-g2 and A0207-ex3-g4 were transfected together with purified Cas9 protein into 1383D2 iPS cells having the HLA haplotypes shown in Table 4 below. Transfection was performed using a commercially available kit (model number "CRISPR-MAX", product number: CMAX00003, Thermo Fisher Scientific).
[0181] [Table 4]
[0182] Next, genomic DNA was extracted and the efficiency of gene mutation introduction in each cell line was examined by T7 endonuclease I (T7EI) assay. The T7EI assay was performed as follows.
[0183] First, nested PCR was performed using primers that specifically amplify the A*02:07 allele in the HLA-A2 region. The primers shown in Table 5 below were used for nested PCR.
[0184] [Table 5]
[0185] Next, the PCR product was purified, and 1 / 10 volume of 10x NEBuffer2 (NEB) buffer was added to the purified PCR product (400 ng), and the double-stranded DNA was thermally denatured by heating at 95°C for 5 minutes, and then reannealed by gradually lowering the temperature. More specifically, the mixture was cooled from 95°C to 85°C at -2°C / sec, and then cooled from 85°C to 25°C at -0.1°C / sec.
[0186] Next, 10 units of T7 endonuclease I (T7EI, Cat. No. M0302S, NEB) was added to the reannealed PCR product and treated for 15 minutes at 37° C. Next, T7EI activity was stopped by adding 1 / 10 the volume of the reaction solution of 0.25 M EDTA solution, and the sample was then kept at a low temperature (on ice).
[0187] Subsequently, the T7EI-treated PCR products were subjected to 2% agarose gel electrophoresis, and the DNA signal intensities of the cleaved and uncleaved bands were quantified using ImageJ software.
[0188] Figure 5(b) shows the results of analyzing the efficiency of genomic DNA mutation introduction using each sgRNA by T7EI assay. In Figure 5(b), "T7EI" indicates T7 endonuclease I, "-" indicates that it was not added, and "+" indicates that it was added. "ex3-g1" indicates the result of introducing A0207-ex3-g1, "ex3-g2" indicates the result of introducing A0207-ex3-g2, "ex3-g4" indicates the result of introducing A0207-ex3-g4, and "DMD#1" indicates the result of introducing sgRNA specific to the dystrophin gene used as a positive control. The arrowhead indicates the band cleaved by T7EI.
[0189] As a result, it was revealed that A0207-ex3-g4 sgRNA had the highest genome cleavage activity.
[0190] [Experimental Example 7] (HLA allele-specific knockout 1) 《Confirmation of HLA protein expression》 To confirm the expression of HLA on the cell surface, two iPS cell lines (1383D2 and 404C2) with HLA antigen type A2 were selected. In addition, 604B1 was selected as an iPS cell line that does not have HLA antigen type A2. A total of three undifferentiated iPS cell lines were stained with anti-HLA-A2 antibody (product number: 740082, BD) and subjected to flow cytometry analysis in the cases where they were not treated with cytokines and where they were treated with 50 ng / mL IFN-γ for 48 hours.
[0191] 6(a) is a graph showing the results of flow cytometry analysis, which confirmed that IFN-γ treatment induced specific expression of HLA-A2 in 1383D2 cells and 404C2 cells.
[0192] <HLA allele-specific knockout> Next, the above-mentioned sgRNAs, A0207-ex3-g1 (target nucleotide sequence shown in SEQ ID NO: 3), A0207-ex3-g2 (target nucleotide sequence shown in SEQ ID NO: 4), and A0207-ex3-g4 (target nucleotide sequence shown in SEQ ID NO: 7), were transfected into 1383D2 iPS cells together with purified Cas9 protein. Transfection was performed using a commercially available kit (type "CRISPR-MAX", product number: CMAX00003, Thermo Fisher Scientific).
[0193] In addition, as a control sgRNA that does not destroy the HLA gene, sgRNA-DMD#1 (target nucleotide sequence shown in SEQ ID NO: 61) targeting the dystrophin (DMD) gene on the X chromosome was used.
[0194] Next, each transfected iPS cell was passaged in two wells, one of which was left untreated with cytokines, while the other was treated with 50ng / mL IFN-γ in the medium for 48 hours, and then analyzed by flow cytometry using anti-HLA-A2 antibody (product number: 740082, BD).
[0195] Figure 6(b) is a graph showing the results of flow cytometry analysis. As a result, it was revealed that the most cells with destroyed HLA-A2 antigen appeared when A0207-ex3-g4 sgRNA, which had the highest genome cleavage activity, was used.
[0196] <Analysis of the base sequence of the sgRNA target site> Next, genomic DNA was extracted from 1383D2 iPS cells into which sgRNA (A0207-ex3-g4) had been introduced, and the A*02:07 allele was specifically amplified. Nested PCR was performed using primers that do not amplify the A*32:01 allele to amplify the target site of the sgRNA. The primers shown in Table 6 below were used for nested PCR.
[0197] [Table 6]
[0198] The PCR products were then cloned into the pGEM-T-Easy vector (Promega) by TA cloning. 21 E. coli colonies were then collected and sequenced by Sanger sequencing. As a result, it was revealed that 11 strains had wild-type sequences, but 10 strains (4 deletion strains and 6 insertion strains) had some kind of insertion-deletion mutation (Indel mutation).
[0199] In addition, 1383D2 iPS cells transfected with sgRNA (A0207-ex3-g4) were stained with anti-HLA-A2 antibody (product number: 740082, BD), and cells that were negative for HLA-A2 antigen were sorted using a flow cytometer. Genomic DNA was extracted from the sorted iPS cells, and nested PCR was performed using primers (described above) that specifically amplify the target allele, A*02:07 allele. In addition, nested PCR was performed using primers that specifically amplify the non-target A*32:01 allele. The primers shown in Table 7 below were used for nested PCR of the A*32:01 allele.
[0200] [Table 7]
[0201] The PCR products were then cloned into the pGEM-T-Easy vector (Promega) by TA cloning. Sixteen E. coli colonies (A*02:07 allele) and 19 (A*32:01 allele) were collected and their base sequences were determined by Sanger sequencing. Based on the determined base sequences, the number of clones with deletions, insertions, and no sequence changes were counted.
[0202] As a result, the A*02:07 allele was found to have some kind of indel mutation in all 16 subclones, whereas the A*32:01 allele was found to have the wild-type sequence in all 19 subclones.
[0203] Figure 7 is a graph showing the efficiency of genomic DNA mutation introduction in the case where sgRNA was introduced into the iPS cell line 1383D2 to induce genome editing, and then sorting based on HLA-A2 antigen expression was not performed, and in the case where a cell group that was negative for HLA-A2 antigen expression was sorted.
[0204] As a result, it was found that sorting HLA antigen-negative cells increased the proportion of cells in which the A*02:07 target allele was edited, and it was also confirmed that no mutations were introduced into the non-target HLA-A*32:01 allele.
[0205] [Experimental Example 8] (HLA allele-specific knockout 2) By destroying the HLA alleles of 604B1 iPS cells having the HLA haplotype in Table 8 below, we produced low antigenic cells with reduced rejection when allogeneic transplantation was performed on recipient A having the hypothetical HLA haplotype shown in Table 9 below. The HLA haplotypes shown in Table 9 below are the HLA haplotypes of peripheral blood mononuclear cells (PBMC, type "LP_194", CTL).
[0206] As shown in Tables 8 and 9, 604B1 iPS cells have the A*01:01 allele and the B*07:02 allele. These HLA alleles are not present in recipient A. For this reason, when 604B1 iPS cells or cells induced to differentiate from 604B1 iPS cells are transplanted into a recipient, they are attacked by T cells of recipient A, resulting in immune rejection.
[0207] Therefore, in order to reduce the rejection reaction, the A*01:01 allele and the B*07:02 allele, which are HLA alleles present in donor cells but not in recipient A, can be destroyed to prevent the expression of HLA proteins specific to donor cells.
[0208] [Table 8]
[0209] [Table 9]
[0210] From the sgRNAs identified in Experimental Example 1 above, two sgRNAs were selected that cleave only the A*01:01 allele and have a base sequence that does not match the A*24:02 allele (A0101-ex3-g1 (the target base sequence is shown in SEQ ID NO: 45) and A0101-ex3-g2 (the target base sequence is shown in SEQ ID NO: 46)) and two sgRNAs that cleave only the B*07:02 allele and have a sequence that does not match the B*37:01 allele (B0702-ex2-g1 (the target base sequence is shown in SEQ ID NO: 47) and B0702-ex2-g2 (the target base sequence is shown in SEQ ID NO: 48)).
[0211] Next, each of the above sgRNAs was synthesized by in vitro transcription reaction and transfected into 604B1 iPS cells together with purified Cas9 protein. Transfection was performed using a commercially available kit (model number "CRISPR-MAX", product number: CMAX00003, Thermo Fisher Scientific).
[0212] Upon introduction of sgRNA, the A*01:01 allele or B*07:02 allele is cleaved. If a genetic mutation occurs during the repair process, the A*01:01 allele or B*07:02 allele is knocked out, resulting in cells lacking HLA-A1 protein or HLA-B7 protein.
[0213] Next, each iPS cell was stimulated with 50ng / mL IFN-γ for 48 hours to induce HLA protein expression. Next, each iPS cell was stained with anti-HLA-A1 antibody (type "ab33883", Abcam) or anti-HLA-B7 antibody (type "MCA986", Bio-Rad), and the proportion of HLA protein-negative cells was analyzed by flow cytometry.
[0214] Figures 8(a) and (b) are graphs showing the results of flow cytometry analysis. Figure 8(a) shows the results of measuring the expression level of HLA-A1 protein in iPS cells in which the A*01:01 allele was destroyed, and Figure 8(b) shows the results of measuring the expression level of HLA-B7 protein in iPS cells in which the B*07:02 allele was destroyed. In Figures 8(a) and (b), "No transfection" shows the results of iPS cells in which sgRNA was not introduced.
[0215] As a result, it was revealed that when A0101-ex3-g1 (target base sequence shown in SEQ ID NO: 45) was used as sgRNA, 11.2% of the cells lost HLA-A1 protein. In addition, when A0101-ex3-g2 (target base sequence shown in SEQ ID NO: 46) was used as sgRNA, 18.9% of the cells lost HLA-A1 protein. From these results, it was revealed that A0101-ex3-g2 is an sgRNA with higher knockout efficiency.
[0216] In addition, when B0702-ex2-g1 (target base sequence shown in SEQ ID NO: 47) was used as sgRNA, it was revealed that 11.6% of cells had lost HLA-B7 protein. In addition, when B0702-ex2-g2 (target base sequence shown in SEQ ID NO: 48) was used as sgRNA, it was revealed that 0.7% of cells had lost HLA-B7 protein. From these results, it was revealed that B0702-ex2-g1 is an sgRNA with higher knockout efficiency.
[0217] From these results, A0101-ex3-g2 and B0702-ex2-g1, which showed high knockout efficiency, were selected, and both the A*01:01 allele and the B*07:02 allele were knocked out. Specifically, the two selected sgRNAs were transfected together with purified Cas9 protein into 604B1 iPS cells. Transfection was performed using a commercially available kit (model number "CRISPR-MAX", product number: CMAX00003, Thermo Fisher Scientific).
[0218] Next, the iPS cells were stimulated with 50ng / mL IFN-γ for 48 hours to induce the expression of HLA proteins.The iPS cells were then stained with anti-HLA-A1 antibody (type "ab33883", Abcam) and anti-HLA-B7 antibody (type "MCA986", Bio-Rad) and analyzed by flow cytometry.
[0219] Figures 9(a) and (b) are graphs showing the results of flow cytometry analysis. In Figure 9(a), "No transfection" indicates the analysis results of iPS cells into which no sgRNA was introduced. In Figure 9(b), "A0101-ex3-g2" and "B0702-ex2-g1" indicate the analysis results of iPS cells into which these two sgRNAs were co-introduced to knock out both the A*01:01 allele and the B*07:02 allele.
[0220] In addition, single-cell sorting was performed from a cell population negative for both HLA-A1 and HLA-B7 proteins, and 15 subclones were collected. Genomic DNA was then extracted from each subclone. PCR reactions were then performed to amplify the region containing the target site (exon 3) of the sgRNA A0101-ex3-g2 used, and the region containing the target site (exon 2) of B0702-ex2-g1, and the base sequences were analyzed by Sanger sequencing.
[0221] Figure 10(a) shows the nucleotide mutation pattern of each recovered clone. In Figure 10(a), "WT" indicates that the nucleotide sequence was wild-type, "-" indicates that it had a deletion mutation, and "+" indicates that it had an insertion mutation. For example, "-5bp" indicates that it had a deletion of 5 nucleotides, and "+18bp" indicates that it had an insertion of 18 nucleotides. Figure 10(b) shows the nucleotide sequences of two strains (#8 and #10) as representative examples.
[0222] As a result, it was revealed that some kind of insertion deletion mutation (Indel mutation) occurred in both the A*01:01 allele and the B*07:02 allele in 11 of the 15 clones. Among the 11 clones with Indel mutations, two clones (#8 and #10) with frameshift mutations were selected and used in the following experiments.
[0223] [Experimental Example 9] (HLA allele-specific knockout 3) By destroying the HLA alleles of 585A1 iPS cells having the HLA haplotype in Table 10 below, we produced low antigenic cells with reduced rejection when allogeneic transplantation was performed on recipient B having the hypothetical HLA haplotype shown in Table 11 below. The HLA haplotypes shown in Table 11 below are the HLA haplotypes of peripheral blood mononuclear cells (PBMC, type "2010113203", Wako).
[0224] As shown in Tables 10 and 11, 585A1 iPS cells have the B*07:02 allele and the C*07:02 allele. These HLA alleles are not present in recipient B. For this reason, when 585A1 iPS cells or cells induced to differentiate from 585A1 iPS cells are transplanted into a recipient, they are attacked by T cells of recipient B, resulting in immune rejection.
[0225] Therefore, in order to reduce the rejection reaction, the B*07:02 allele and the C*07:02 allele, which are HLA alleles that are not present in recipient B but are present in donor cells, can be destroyed so that the donor cells do not express HLA proteins specific to the donor cells.
[0226] [Table 10]
[0227] [Table 11]
[0228] As sgRNA, B0702-ex2-g1 specific to the B*07:02 allele (target nucleotide sequence shown in SEQ ID NO: 47) and C0702-ex3-g3 specific to the C*07:02 allele (target nucleotide sequence shown in SEQ ID NO: 49) were used. In addition, knockout of both the B*07:02 allele and the C*07:02 allele of 585A1 iPS cells was performed in the same manner as in Experimental Example 7, except that a commercially available kit (product name "4D-Nucleofector", model number "V4XP-4032", Lonza) was used for transfection.
[0229] Next, the iPS cells were stimulated with 50 ng / mL IFN-γ for 48 hours to induce the expression of HLA proteins.Then, the iPS cells were stained with an anti-HLA-B7 antibody (model number "MCA986", Bio-Rad) and analyzed by flow cytometry.
[0230] Figure 11 is a graph showing the results of flow cytometry analysis. In Figure 11, "No stain" indicates the analysis result of iPS cells that were not stained with an antibody, "No transfection" indicates the analysis result of iPS cells that were not introduced with sgRNA, and "B0702-ex2-g1" and "C0702-ex3-g3" indicate the analysis result of iPS cells into which these sgRNAs were introduced to knock out both the B*07:02 allele and the C*07:02 allele.
[0231] In addition, single-cell sorting was performed from a cell population negative for HLA-B7 protein, and 28 subclones were collected. Genomic DNA was then extracted from each subclone. PCR reactions were then performed to amplify the region containing the target site (exon 2) of the sgRNA B0702-ex2-g1 used, and the region containing the target site (exon 3) of C0702-ex3-g3, and the base sequence was analyzed by Sanger sequencing.
[0232] Figure 12 shows the nucleotide mutation patterns of each of the recovered clones. In Figure 12(a), "WT" indicates that the nucleotide sequence was wild-type, "-" indicates that the clone had a deletion mutation, and "+" indicates that the clone had an insertion mutation. Figure 12(b) shows the nucleotide sequences of three strains (#2, #11, and #26) as representative examples.
[0233] As a result, it was revealed that some kind of insertion deletion mutation (Indel mutation) occurred in both the B*07:02 allele and the C*07:02 allele in several clones. Among the clones with Indel mutation, three strains (#2, #11, and #26) were selected and used in the following experiments.
[0234] [Experimental Example 10] (HLA allele-specific knockout 4) By destroying the HLA alleles of 585A1 iPS cells having the HLA haplotype in Table 12 below, we produced low antigenic cells with reduced rejection when allogeneic transplantation was performed on recipient C having the hypothetical HLA haplotype shown in Table 13 below. The HLA haplotypes shown in Table 13 below are the HLA haplotypes of peripheral blood mononuclear cells (PBMC, type "LP_266", CTL).
[0235] As shown in Tables 12 and 13, 585A1 iPS cells have the B*52:01 allele and the C*12:02 allele. These HLA alleles are not present in recipient C. For this reason, when 585A1 iPS cells or cells induced to differentiate from 585A1 iPS cells are transplanted into recipient C, they are attacked by T cells of recipient C, resulting in immune rejection.
[0236] Therefore, in order to reduce the rejection reaction, the HLA alleles B*52:01 and C*12:02, which are present in donor cells but not in recipient C, can be destroyed to prevent the expression of HLA proteins specific to donor cells.
[0237] [Table 12]
[0238] [Table 13]
[0239] The C*12:02 allele of 585A1 iPS cells was knocked out to obtain 17 subclones in the same manner as in Experimental Example 9, except that the sgRNA used was C1202-ex3-g1 (the target base sequence is shown in SEQ ID NO: 50), which is specific for the C*12:02 allele, and cell sorting was not performed. Cell sorting was not performed because anti-HLA-C12 allele-specific antibodies were not available.
[0240] Genomic DNA was then extracted from each subclone, and PCR was performed to amplify the region containing the target site (exon 3) of the sgRNA C1202-ex3-g1 used, followed by Sanger sequencing.
[0241] Figure 13(a) shows the base mutation pattern of each recovered clone. In Figure 13(a), "-" indicates that the clone had a deletion mutation, and "+" indicates that the clone had an insertion mutation. As a result, it became clear that some kind of insertion deletion mutation (Indel mutation) had occurred near the target site of the sgRNA. Among the clones in which Indel mutations had occurred, #1 cell in which a frameshift mutation had occurred was selected.
[0242] Next, the B*52:01 allele-specific B5201-ex3-g2 (target nucleotide sequence shown in SEQ ID NO: 51) was introduced as sgRNA into the #1 cells in which the C*12:02 allele was knocked out to knock out the B*52:01 allele, and 12 subclones (clones #1-1 to #1-12) were obtained. Cell sorting was not performed because anti-HLA-B52 allele-specific antibodies were not available.
[0243] Genomic DNA was then extracted from each subclone, and PCR was performed to amplify the region containing the target site (exon 3) of the sgRNA B5201-ex3-g2 used, followed by analysis of the base sequence by Sanger sequencing.
[0244] Figure 13(b) shows the nucleotide mutation patterns of each of the recovered clones. In Figure 13(b), "Mut" indicates that the clone had a substitution mutation, "WT" indicates that the clone had a wild-type nucleotide sequence, and "-" indicates that the clone had a deletion mutation. As a result, it became clear that some mutation had occurred near the target site of the sgRNA. Figure 13(c) shows the nucleotide sequence of strain #1-1 as a representative example.
[0245] [Experimental Example 11] (HLA allele-specific knockout 5) By destroying the HLA alleles of 604B1 iPS cells having the HLA haplotype in Table 14 below, we produced low antigenic cells with reduced rejection when allogeneic transplantation was performed on recipient C having the hypothetical HLA haplotype shown in Table 15 below. The HLA haplotypes shown in Table 15 below are the HLA haplotypes of peripheral blood mononuclear cells (PBMC, type "LP_266", CTL).
[0246] As shown in Tables 14 and 15, 604B1 iPS cells have the A*01:01 allele, the B*37:01 allele, and the C*06:02 allele. These HLA alleles are not present in recipient C. For this reason, when 604B1 iPS cells or cells induced to differentiate from 604B1 iPS cells are transplanted into a recipient, they are attacked by T cells of the recipient, resulting in immune rejection.
[0247] Therefore, in order to reduce the rejection reaction, the HLA alleles A*01:01, B*37:01 and C*06:02 present in the donor cells but not in the recipient C can be destroyed to prevent the expression of HLA proteins specific to the donor cells.
[0248] [Table 14]
[0249] [Table 15]
[0250] As the sgRNA, A0101-ex3-g2 (target base sequence shown in SEQ ID NO: 46) specific to the A*01:01 allele was used to knock out the A*01:01 allele of 604B1 iPS cells in the same manner as in Experimental Example 9. Next, C0602-ex3-g1 (target base sequence shown in SEQ ID NO: 52), which is an sgRNA specific to the C*06:02 allele, was introduced into the cells to knock out the C*06:02 allele, and nine subclones were obtained.
[0251] Next, genomic DNA was extracted from each subclone, and PCR was performed to amplify the region containing the target site (exon 3) of the sgRNA A0101-ex3-g2 and the region containing the target site (exon 3) of C0602-ex3-g1, respectively, and the base sequence was analyzed by Sanger sequencing.
[0252] FIG. 14(a) shows the base mutation pattern of each clone recovered. In FIG. 14(a), "WT" indicates that the base sequence was wild-type, "-" indicates that the base sequence had a deletion mutation, and "+" indicates that the base sequence had an insertion mutation. As a result, clones were obtained in which some kind of insertion deletion mutation (Indel mutation) occurred near the target site of the sgRNA. In FIG. 14(b), the base sequence of clone #3, which had a frameshift mutation, is shown as a representative example from among the clones in which an Indel mutation occurred.
[0253] Next, we introduced HLA-B allele-specific B-ex2-g1 (target nucleotide sequence shown in SEQ ID NO: 53) as sgRNA into clone #3 in which the A*01:01 allele and the C*06:02 allele were knocked out, and attempted to obtain a clone in which only the B*37:01 allele was knocked out. Note that B-ex2-g1 is an sgRNA that targets both the B*37:01 allele and the B*07:02 allele.
[0254] Next, the iPS cells were stimulated with 50 ng / mL IFN-γ for 48 hours to induce the expression of HLA proteins.Then, the iPS cells were stained with an anti-HLA-B7 antibody (model number "MCA986", Bio-Rad) and analyzed by flow cytometry.
[0255] Figure 15(a) is a graph showing the results of flow cytometry analysis. In Figure 15(a), "No stain" indicates the analysis result of iPS cells that were not stained with an antibody, "No transfection" indicates the analysis result of iPS cells that were not transfected with sgRNA, and "B-ex2-g1" indicates the analysis result of iPS cells that were transfected with this sgRNA to knock out the HLA-B allele.
[0256] In addition, single-cell sorting was performed from a cell population positive for HLA-B7 protein, and 12 subclones (clones #3-1 to #3-12) were collected. Genomic DNA was then extracted from each subclone. Next, PCR reactions were performed to amplify the targeted B*37:01 allele and the non-targeted B*07:02 allele in the region containing the target site (exon 2) of the sgRNA B-ex2-g1 used, and the base sequence was analyzed by Sanger sequencing.
[0257] FIG. 15(b) shows the nucleotide mutation patterns of each of the recovered clones. In FIG. 15(b), "Mut" indicates that the clone had a substitution mutation, "WT" indicates that the clone had a wild-type nucleotide sequence, "-" indicates that the clone had a deletion mutation, and "+" indicates that the clone had an insertion mutation. As a result, clones were obtained in which some kind of insertion deletion mutation (Indel mutation) occurred near the target site of the sgRNA. In FIG. 15(c), the nucleotide sequences of two clones (clones #3-11 and #3-12) are shown as representative examples from among the clones in which an Indel mutation occurred only in the B*37:01 allele.
[0258] [Experimental Example 12] (HLA allele-specific knockout 6) Cells were produced in which all three loci of HLA-A alleles, HLA-B alleles, and HLA-C alleles were knocked out by disrupting the HLA alleles of 604B1 iPS cells having the HLA haplotypes shown in Table 16. Figure 16(a) shows the target sites of the sgRNA used in this experimental example.
[0259] [Table 16]
[0260] Using BC-ex2-g1 (the target base sequence is shown in SEQ ID NO:54) as the sgRNA, which can target both HLA-B and HLA-C alleles, the B*07:02 allele, B*37:01 allele, C*06:02 allele, and C*07:02 allele of 604B1 iPS cells were knocked out in the same manner as in Experimental Example 9.
[0261] Next, the iPS cells were stimulated with 50 ng / mL IFN-γ for 48 hours and subjected to flow cytometry analysis to examine the expression of HLA-B protein and HLA-C protein. Figure 16(b) is a graph showing the results of flow cytometry. In Figure 16(b), "No stain" indicates the analysis result of iPS cells that were not stained with an antibody, "No transfection" indicates the analysis result of iPS cells that were not introduced with sgRNA, and "BC-ex2-g1" indicates the analysis result of iPS cells that were introduced with this sgRNA to knock out both HLA-B allele and HLA-C allele.
[0262] Then, a cell population negative for both HLA-B and HLA-C proteins was sorted and collected. Then, A-ex3-g1 (target nucleotide sequence shown in SEQ ID NO: 55), which can target both alleles of the HLA-A gene, was introduced into the collected cell population to knock out the A*01:01 allele and the A*24:02 allele.
[0263] Next, the iPS cells were stimulated with 50 ng / mL IFN-γ for 48 hours and subjected to flow cytometry analysis to examine the expression of HLA-A protein, HLA-B protein, and HLA-C protein. Figure 16(c) is a graph showing the results of flow cytometry. In Figure 16(c), "No stain" indicates the analysis result of iPS cells that were not stained with an antibody, "No transfection" indicates the analysis result of iPS cells that were not introduced with sgRNA, and "A-ex3-g1" indicates the analysis result of iPS cells that were introduced with this sgRNA to knock out the HLA-A allele.
[0264] Next, single-cell sorting of cell populations negative for HLA-A, HLA-B and HLA-C proteins was performed, and eight subclones were collected. Genomic DNA was then extracted from each subclone. PCR reactions were then performed to amplify the regions containing the target sites of the sgRNAs used, and the base sequences were analyzed by Sanger sequencing.
[0265] FIG. 17(a) shows the nucleotide mutation pattern of one of the recovered clones (clone #1). In FIG. 17(a), "-" indicates that the clone had a deletion mutation, and "+" indicates that the clone had an insertion mutation. As a result, it was confirmed that clones were obtained in which insertion and deletion mutations (Indel mutations) occurred in all of the A*01:01 allele, A*24:02 allele, B*07:02 allele, B*37:01 allele, C*06:02 allele, and C*07:02 allele. FIG. 17(b) shows the nucleotide sequence of each HLA allele of clone #1. In FIG. 17(b), "WT" indicates the wild-type nucleotide sequence.
[0266] [Experimental Example 13] (HLA allele-specific knockout 7) By disrupting the HLA alleles of 585A1 iPS cells having the HLA haplotype in Table 17 below, cells were produced in which the HLA-A allele and the HLA-B allele were knocked out and only one of the HLA-C alleles was knocked out.
[0267] [Table 17]
[0268] As sgRNAs, A-ex3-g1 (target nucleotide sequence shown in SEQ ID NO: 55) capable of targeting the HLA-A allele and B-ex2-g1 (target nucleotide sequence shown in SEQ ID NO: 53) capable of targeting the HLA-B allele were used to knock out the A*24:02 allele, B*07:02 allele and B*52:01 allele of 585A1 iPS cells in the same manner as in Experimental Example 9.
[0269] Next, the iPS cells were stimulated with 50 ng / mL IFN-γ for 48 hours and subjected to flow cytometry analysis to examine the expression of HLA-A24 antigen and HLA-B7 antigen. Figure 18(a) is a graph showing the results of flow cytometry.
[0270] Next, single-cell sorting of cell populations negative for both HLA-A24 and HLA-B7 antigens was performed, and 10 subclones were collected. Genomic DNA was then extracted from each subclone. PCR reactions were then performed to amplify the regions containing the target sites of the sgRNAs used, and the base sequences were analyzed by Sanger sequencing.
[0271] FIG. 18(b) shows the nucleotide mutation pattern of each of the recovered clones. In FIG. 18(b), "WT" indicates that the nucleotide sequence was wild type, "-" indicates that it had a deletion mutation, "+" indicates that it had an insertion mutation, and "?" indicates that it could not be determined. As a result, clone #3 was selected, which clearly showed that an insertion deletion mutation (Indel mutation) occurred in all of the A*24:02 allele, B*07:02 allele, and B*52:01 allele. FIG. 18(c) shows the nucleotide sequence of clone #3.
[0272] Next, C1202-ex3-g1 (target base sequence shown in SEQ ID NO: 50) specific to the C*12:02 allele was introduced into clone #3 to knock out the C*12:02 allele. Then, four subclones (clones #3-1 to #3-4) were collected. Then, genomic DNA was extracted from each subclone. Next, PCR reactions were performed to amplify the C*07:02 allele and the C*12:02 allele, respectively, and the base sequences were analyzed by Sanger sequencing.
[0273] FIG. 18(d) shows the nucleotide mutation pattern of each of the recovered clones. In FIG. 18(d), "WT" indicates a wild-type nucleotide sequence, and "-" indicates a deletion mutation. As a result, it was confirmed that the C*07:02 allele remained, and three clones (clones #3-1, #3-2, and #3-3) in which an insertion deletion mutation (Indel mutation) occurred in the C*12:02 allele were obtained. FIG. 18(e) shows the nucleotide sequence of clone #3-1 as a representative example.
[0274] [Experimental Example 14] (HLA allele-specific knockout 8) By disrupting the HLA alleles of 604B1 iPS cells having the HLA haplotypes in Table 18 below, cells in which the HLA-A allele and the HLA-B allele were knocked out were generated.
[0275] [Table 18]
[0276] Using sgRNAs A-ex3-g1 (the target base sequence is shown in SEQ ID NO: 55) capable of targeting the HLA-A allele and B-ex2-g1 (the target base sequence is shown in SEQ ID NO: 53) capable of targeting the HLA-B allele, the A*01:01 allele, A*24:02 allele, B*07:02 allele and B*37:01 allele of 604B1 iPS cells were knocked out in the same manner as in Experimental Example 9.
[0277] Next, the iPS cells were stimulated with 50 ng / mL IFN-γ for 48 hours and subjected to flow cytometry analysis to examine the expression of HLA-A24 antigen and HLA-B7 antigen. Figure 19(a) is a graph showing the results of flow cytometry. In Figure 19(a), "No stain" indicates the analysis result of iPS cells that were not stained with an antibody, "No transfection" indicates the analysis result of iPS cells that were not introduced with sgRNA, and "A-ex2-g1" and "B-ex2-g1" indicate the analysis result of iPS cells that were introduced with these sgRNAs to knock out both the HLA-A allele and the HLA-B allele.
[0278] Next, the cell population negative for both HLA-A24 antigen and HLA-B7 antigen was sorted and collected, and the expression of HLA-A1 antigen was further examined. Figure 19(b) is a graph showing the results of flow cytometry. In Figure 19(b), "No stain" indicates the analysis result of iPS cells that were not stained with antibodies, and "HLA-A24, B7(-) sorted" indicates the analysis result of the sorted cell population negative for both HLA-A24 antigen and HLA-B7 antigen.
[0279] Next, the cell population negative for HLA-A1 antigen was sorted and collected, and 23 subclones were collected. Genomic DNA was then extracted from each subclone. After PCR was performed to amplify the region containing the target site of the sgRNA used, the base sequences of the seven strains were analyzed by Sanger sequencing.
[0280] FIG. 19(c) shows the nucleotide mutation pattern of each of the recovered clones. In FIG. 19(c), "WT" indicates that the nucleotide sequence was wild-type, "-" indicates that the nucleotide sequence had a deletion mutation, and "+" indicates that the nucleotide sequence had an insertion mutation. As a result, it was revealed that six clones were obtained in which an insertion deletion mutation (Indel mutation) occurred in all of the A*01:01 allele, the A*24:02 allele, the B*07:02 allele, and the B*37:01 allele. As a representative example, the nucleotide sequence of clone #4 is shown in FIG. 19(d).
[0281] [Experimental Example 15] (HLA allele-specific knockout 9) Cells were generated in which all three loci of HLA-A allele, HLA-B allele, and HLA-C allele were knocked out by disrupting the HLA allele of 1383D2 iPS cells having the HLA haplotypes shown in Table 19. Figure 20(a) shows the target site of the sgRNA used in this experimental example.
[0282] [Table 19]
[0283] Using BC-ex2-g1 (the target base sequence is shown in SEQ ID NO: 54) as an sgRNA capable of targeting both HLA-B and HLA-C alleles, the B*15:02 allele, B*51:01 allele, C*08:01 allele, and C*14:02 allele of 1383D2 iPS cells were knocked out in the same manner as in Experimental Example 9.
[0284] Next, the iPS cells were stimulated with 50 ng / mL IFN-γ for 48 hours and subjected to flow cytometry analysis to examine the expression of HLA-B protein and HLA-C protein. Figure 20(b) is a graph showing the results of flow cytometry. In Figure 20(b), "No stain" indicates the analysis result of iPS cells that were not stained with an antibody, "No transfection" indicates the analysis result of iPS cells that were not introduced with sgRNA, and "BC-ex2-g1" indicates the analysis result of iPS cells that were introduced with this sgRNA to knock out both HLA-B allele and HLA-C allele.
[0285] Then, a cell population negative for both HLA-B and HLA-C proteins was sorted and collected. Then, A-ex3-g1 (target nucleotide sequence shown in SEQ ID NO: 55), which can target both alleles of the HLA-A gene, was introduced into the collected cell population to knock out the A*02:07 allele and the A*32:01 allele.
[0286] Next, the iPS cells were stimulated with 50 ng / mL IFN-γ for 48 hours and subjected to flow cytometry analysis to examine the expression of HLA-A protein, HLA-B protein, and HLA-C protein.
[0287] FIG. 20(c) is a graph showing the results of flow cytometry. In FIG. 20(c), "No stain" indicates the analysis result of iPS cells that were not stained with an antibody, "No transfection" indicates the analysis result of iPS cells that were not introduced with sgRNA, and "A-ex3-g1" indicates the analysis result of iPS cells in which the sgRNA was introduced to knock out the HLA-A allele. As a result, the presence of a cell population that was negative for all of the HLA-A protein, HLA-B protein, and HLA-C protein was confirmed.
[0288] [Experimental Example 16] (Modification of HLA alleles) We investigated whether the A*02:07 allele of 1383D2 iPS cells, which have the HLA haplotype in Table 20 below, could be modified to the A*01:01 allele by genome editing.
[0289] [Table 20]
[0290] First, a dual-regulated Cas9 expression vector and an sgRNA expression vector, both of which are piggyBac transposon vectors, were introduced into 1383D2 iPS cells, and a population of cells with stable chromosome introduction was obtained by drug selection for approximately 5 days using puromycin (Cat. No. 29455-54, Nacalai Tesque) at a final concentration of 1 to 15 μg / mL or hygromycin B (Cat. No. 10687-010, Thermo Fisher Scientific) at a final concentration of 100 to 200 μg / mL.
[0291] The dual-regulatory Cas9 expression vector is an expression vector for Cas9 that can control both expression induction and intracellular localization (Ishida et al., Site-specific randomization of the endogenous genome by a regulatable CRISPR-Cas9 piggyBac system in human cells, Sci. Rep., 8: 310, 2018). In this experimental example, a dual-regulatory Cas9 expression vector was used that can induce the expression of a fusion protein of Cas9 protein and glucocorticoid receptor (GR) (hereinafter referred to as "Cas9-GR protein") by adding doxycycline (Dox) to the cell culture medium, and can translocate Cas9-GR into the nucleus by adding dexamethasone (Dex) to the cell culture medium. In addition, A0207-ex3-g1 (the target nucleotide sequence is shown in SEQ ID NO: 3) was used as the sgRNA.
[0292] 21(a) and (b) are schematic diagrams illustrating homologous recombination according to this experimental example. Next, in order to induce homologous recombination, a single-stranded DNA (the target base sequence is shown in SEQ ID NO:56) encoding a region including exons 1 to 3 of the A*01:01 allele was prepared.
[0293] Specifically, first, using the genomic DNA of 604B1 iPS cells as a template, the portion from 67 bases upstream of exon 1 to 1,247 bases downstream of exon 3 of the A*01:01 allele was amplified by PCR using the primers shown in Table 21 below, and then inserted into the pENTR plasmid to produce the pENTR vector.
[0294] [Table 21]
[0295] Next, this plasmid DNA was treated with nicking endonuclease Nb.BsrDI enzyme (product number "R0648S", New England Biolabs), and subjected to agarose electrophoresis under formamide denaturing conditions. The corresponding DNA band was excised and purified to prepare the desired single-stranded DNA donor (lssDNA donor, sequence number 56).
[0296] Next, the pENTR vector (dsDNA donor) in a double-stranded DNA state or the prepared single-stranded DNA (lssDNA donor, sequence number 56) was introduced into 1383D2 iPS cells, and Dox and Dex were added at final concentrations of 2 μM and 1 μM, respectively, to induce homologous recombination by genome editing.
[0297] Next, each iPS cell was stimulated with 50 ng / mL IFN-γ for 48 hours and subjected to flow cytometry analysis to examine the expression of HLA-A2 antigen and HLA-A1 antigen.
[0298] Figure 21(c) is a graph showing the results of flow cytometry. In Figure 20(c), "No stain" indicates the analysis result of iPS cells that were not stained with an antibody, "No Dox / Dex" indicates the analysis result of iPS cells in which Cas9 expression was not induced, "dsDNA donor" indicates the analysis result of iPS cells in which a double-stranded DNA donor was introduced to induce homologous recombination, and "lssDNA donor" indicates the analysis result of iPS cells in which a single-stranded DNA donor was introduced to induce homologous recombination.
[0299] As a result, the rate of A2 antigen-negative and A1 antigen-positive individuals was 0.2% when double-stranded DNA was used as the donor, whereas it was 1.6% when single-stranded DNA was used as the donor.
[0300] Next, the cell population that had become A2 antigen negative and A1 antigen positive by homologous recombination using a single-stranded DNA donor was sorted by flow cytometry, and the base sequence of the HLA-A locus was analyzed for the cell population itself and for the subclones after single-cell sorting.
[0301] Figure 22(a) shows the results of analyzing the base sequence of the cell population as is. In Figure 22(a), "Bulk" indicates the results of analyzing the cell population as is. As a result, it was revealed that cells in which part of the A*02:07 locus (especially the 5' side of exon 2 and exon 3) was modified to the A*01:01 gene were mixed in.
[0302] 22(b) shows the results of analyzing the base sequence of a representative subclone (clone #2) obtained by single-cell sorting, revealing that a part of the A*02:07 locus was altered to the A*01:01 gene.
[0303] [Experimental Example 17] (Creation of B2M knockout iPS cells 1) 1383D2 iPS cells were transfected with a plasmid vector expressing Cas9 and B2M-specific sgRNA. The sgRNAs used were B2M-g1 (target nucleotide sequence shown in SEQ ID NO: 59) and B2M-g2 (target nucleotide sequence shown in SEQ ID NO: 60).
[0304] Next, cells stimulated with 50 ng / mL IFN-γ for 48 hours were stained with anti-HLA-ABC antibody and subjected to flow cytometry analysis.
[0305] Figure 23(a) is a graph showing the results of flow cytometry. In Figure 23(a), "No stain" indicates the analysis result of iPS cells that were not stained with an antibody, "No transfection" indicates the analysis result of iPS cells that were not transfected with sgRNA, and "B2M-g1" and "B2M-g2" indicate the analysis result of iPS cells in which the sgRNA was transfected to knock out the B2M allele.
[0306] As a result, the percentage of the cell population that was negative for all of the HLA-A protein, HLA-B protein, and HLA-C protein was 2.8% when B2M-g1 (target nucleotide sequence shown in SEQ ID NO: 59) was used as the sgRNA, and 6.9% when B2M-g2 (target nucleotide sequence shown in SEQ ID NO: 60) was used as the sgRNA.
[0307] Next, two subclones, clones #1 and #2, were obtained by single-cell sorting from a cell population that was negative for all of HLA-A, HLA-B, and HLA-C, obtained by introduction of B2M-g2 sgRNA.
[0308] The two subclones obtained were again stimulated with IFN-γ for 48 hours and subjected to flow cytometry analysis. Figure 23(b) is a graph showing the results of flow cytometry. In Figure 23(b), "B2M-KO#1" shows the results for clone #1, and "B2M-KO#2" shows the results for clone #2. As a result, it was confirmed that all clones were negative for HLA-A, HLA-B, and HLA-C.
[0309] Next, the B2M gene of clone #1 was amplified by PCR to confirm the base sequence, and it was confirmed that an insertion deletion mutation (Indel mutation) had been introduced. Figure 23(c) shows the base sequence of the B2M allele of clone #1. In Figure 23(c), "WT" indicates the wild-type base sequence.
[0310] [Experimental Example 18] (Creation of B2M knockout iPS cells 2) The 604B1 iPS cells were subjected to the same procedure as in Experimental Example 17 to knock out the B2M allele. B2M-g2 (the target nucleotide sequence is shown in SEQ ID NO: 60) was used as the sgRNA.
[0311] Next, cells stimulated with 50 ng / mL IFN-γ for 48 hours were stained with anti-HLA-ABC antibody and subjected to flow cytometry analysis.
[0312] FIG. 24(a) is a graph showing the results of flow cytometry. In FIG. 24(a), "No stain" indicates the analysis result of iPS cells that were not stained with an antibody, "No transfection" indicates the analysis result of iPS cells that were not introduced with sgRNA, and "B2M-g2" indicates that the B2M allele was knocked out by introducing this sgRNA. As a result, it was revealed that a cell population that was negative for all of HLA-A protein, HLA-B protein, and HLA-C protein was obtained.
[0313] Subsequently, four subclones, clones #1, #2, #3 and #4, were obtained by single cell sorting from a cell population that was negative for all of HLA-A, HLA-B and HLA-C.
[0314] Next, the B2M genes of these subclones were amplified by PCR to confirm the base sequences. Figure 24(b) shows the results of the analysis of the base sequences. As a result, it was confirmed that an insertion deletion mutation (Indel mutation) was introduced into each of the subclones.
[0315] [Experimental Example 19] (T cell activation test 1) (1) 604B1 iPS cells having the HLA haplotype in Table 22 below, (2) clone #8 produced in Experimental Example 8 in which the A*01:01 allele and B*07:02 allele of 604B1 iPS cells had been knocked out, (3) clone #10 of the same, (4) 1383D2 iPS cells having the HLA haplotype in Table 23 below, and (5) 604B1 iPS cells (clone #1) produced in Experimental Example 18 in which the B2M allele had been knocked out were each induced to differentiate into embryoid body (EB)-derived blood cell-like cells.
[0316] [Table 22]
[0317] [Table 23]
[0318] Next, CD8 positive T cells recovered by sorting from peripheral blood mononuclear cells (PBMC, type "LP_194", CTL, corresponding to the above-mentioned recipient A) having the HLA haplotype in Table 24 below were stained with CFSE (Cayman Chemical Company) and co-cultured for 8 days with EB-derived blood cell-like cells differentiated from each of the above cells (1) to (5) in the presence of IL-2 and IFN-γ.
[0319] [Table 24]
[0320] After co-culture, flow cytometry analysis was performed to examine CFSE fluorescence. Figures 25(a) to (e) are graphs showing the results of flow cytometry. Figures 25(a) to (e) show the results of CD8 positive T cells co-cultured with EB-derived blood cell-like cells differentiated from each of the cells (1) to (5) above. As a result, it was confirmed that only the T cell population that specifically recognized the HLA antigen of each iPS cell proliferated and became CFSE negative.
[0321] [Experimental Example 20] (T cell activation test 2) (1) 585A1 iPS cells having the HLA haplotype in Table 25 below, (2) clone #2 produced in Experimental Example 9 in which the B*07:02 allele and C*07:02 allele of 585A1 iPS cells were knocked out, (3) clone #11, (4) clone #26, (5) 1383D2 iPS cells having the HLA haplotype in Table 26 below, and (6) 604B1 iPS cells (clone #1) produced in Experimental Example 18 in which B2M was knocked out were each induced to differentiate into EB-derived blood cell-like cells.
[0322] [Table 25]
[0323] [Table 26]
[0324] Next, CD8 positive T cells recovered by sorting from peripheral blood mononuclear cells (PBMC, type number "2010113203", Wako, corresponding to recipient B described above) having the HLA haplotypes in Table 27 below were stained with CFSE (Cayman Chemical Company) and co-cultured for 8 days with EB-derived blood cell-like cells differentiated from each of the cells (1) to (6) above in the presence of IL-2 and IFN-γ.
[0325] [Table 27]
[0326] After co-culture, flow cytometry analysis was performed to examine CFSE fluorescence. Figure 26 (a) to (f) are graphs showing the results of flow cytometry. Figure 26 (a) to (f) show the results of CD8 positive T cells co-cultured with EB-derived blood cell-like cells differentiated from each of the cells (1) to (6) above. As a result, it was confirmed that a T cell population that specifically recognized the HLA antigen of each iPS cell proliferated and became CFSE negative.
[0327] [Experimental Example 21] (T cell activation test 3) (1) 604B1 iPS cells having the HLA haplotype in Table 28 below, (2) clone #3-11, (3) clone #3-12, (4) 1383D2 iPS cells having the HLA haplotype in Table 29 below, and (5) 604B1 iPS cells (clone #1) in which B2M was knocked out, (1) clone #3-11, (2) clone #3-12, (3) clone #3-12, (4) 1383D2 iPS cells having the HLA haplotype in Table 29 below, and (5) 604B1 iPS cells (clone #1), (1) prepared in Experimental Example 18, in which B2M was knocked out, were each induced to differentiate into EB-derived blood cell-like cells.
[0328] [Table 28]
[0329] [Table 29]
[0330] Next, CD8 positive T cells recovered by sorting from peripheral blood mononuclear cells (PBMC, type "LP_266", CTL, corresponding to the above-mentioned recipient C) having the HLA haplotype in Table 30 below were stained with CFSE (Cayman Chemical Company) and co-cultured for 8 days with EB-derived blood cell-like cells differentiated from each of the above cells (1) to (5) in the presence of IL-2 and IFN-γ.
[0331] [Table 30]
[0332] After co-culture, flow cytometry analysis was performed to examine CFSE fluorescence. Figures 27(a) to (e) are graphs showing the results of flow cytometry. Figures 27(a) to (e) show the results of CD8 positive T cells co-cultured with EB-derived blood cell-like cells differentiated from each of the cells (1) to (5) above. As a result, it was confirmed that T cell populations that specifically recognized the HLA antigens of each iPS cell proliferated and became CFSE negative.
[0333] [Experimental Example 22] (Preparation of HLA antigen-reactive CD8 positive T cells) We prepared CD8 positive T cells that react with the HLA antigens of 604B1 iPS cells. T cells derived from peripheral blood mononuclear cells (PBMCs) contain a mixture of T cells that recognize a variety of antigens. Among these T cells, CD8 positive T cells that react with the HLA antigens of 604B1 iPS cells were stimulated to proliferate and then collected.
[0334] Figure 28 is a schematic diagram showing the procedure of this experimental example. As shown in Figure 28, first, 604B1 iPS cells were differentiated into EB-derived blood cell-like cells. The EB-derived blood cell-like cells contain CD45-positive white blood cells. Next, CD8-positive T cells contained in PBMCs were stained with CFSE (Cayman Chemical Company), and co-cultured for 8 days with the EB-derived blood cell-like cells differentiated from 604B1 iPS cells in the presence of IL-2 and IFN-γ.
[0335] Next, flow cytometry analysis was performed after co-culture to examine CFSE fluorescence. Figures 29(a) to (e) are graphs showing the results of flow cytometry.
[0336] Fig. 29(a) shows the results of co-culturing a PBMC cell population with an allogeneic (allo) PBMC cell population, Fig. 29(b) shows the results of co-culturing a PBMC cell population with EB-derived hemocyte-like cells differentiated from 604B1 iPS cells, Fig. 29(c) shows the results of culturing only the PBMC cell population, Fig. 29(d) shows the results of co-culturing CD8-positive T cells recovered by sorting from the PBMC cell population with EB-derived hemocyte-like cells differentiated from 604B1 iPS cells, and Fig. 29(e) shows the results of culturing only the CD8-positive T cells recovered by sorting from the PBMC cell population. As a result, it was confirmed that the T cell population that specifically recognizes the incompatible HLA antigen proliferated and became CFSE negative.
[0337] Next, the CD8-positive T cells that had become CFSE-negative, as shown in FIG. 29(d), were sorted and collected to obtain T cells reactive to the HLA antigen of 604B1 iPS cells.
[0338] [Experimental Example 23] (T cytotoxicity test 1) 30 is a schematic diagram showing the procedure of this experimental example. First, (1) 604B1 iPS cells having the HLA haplotypes shown in Table 31 below, (2) clone #8 produced in experimental example 8 in which the A*01:01 allele and the B*07:02 allele of 604B1 iPS cells were knocked out, (3) clone #10 of the same, and (4) 1383D2 iPS cells (clone #1) produced in experimental example 17 in which B2M was knocked out were each induced to differentiate into cardiomyocytes.
[0339] [Table 31]
[0340] Next, each cardiomyocyte was stimulated with IFN-γ to induce the expression of HLA proteins. 51 To perform the Cr release assay, 51 Cr (chromium) was added and allowed to be taken up by each cardiac myocyte.
[0341] Next, CD8+ T cells reactive to the HLA antigen of 604B1 iPS cells prepared in Experimental Example 22 were added at various ratios to the culture medium of each cardiomyocyte, and it was examined whether each cardiomyocyte was attacked. That is, the HLA antigen-reactive CD8 T cells prepared in Experimental Example 22 were used as effector cells, and the above-mentioned iPS cell-derived cardiomyocytes were used as target cells. The ratio of the number of CD8+ T cells added to cardiomyocytes was 0.625, 1.25, 2.5, 5, and 10.
[0342] When cardiomyocytes are attacked by CD8 positive cells, the cells are damaged and 51 Cr is released. 51 By measuring Cr, it is possible to determine whether each myocardial cell has been attacked. 51 This is called the Cr release assay. 51 Cr-labeled and untreated cardiac myocyte supernatant 51 The amount of Cr was defined as 0% specific lysis, and the amount of Cr was reduced by detergent (Triton-X). 51 Released into the supernatant when Cr-labeled cardiomyocytes were killed. 51 From the amount of Cr, in a normal medium 51 Released into the supernatant when Cr-labeled cardiomyocytes were cultured 51 The value minus the amount of Cr was defined as 100% specific lysis.
[0343] Figure 31 is a graph showing the percentage of each type of cardiomyocyte that was injured and dissolved. In Figure 31, "*" indicates that there is a significant difference at P<0.05, "Non-edited" indicates the results for cardiomyocytes induced to differentiate from the 604B1 iPS cells described in (1) above, and "A1 - B7 - #8" indicates the result of cardiomyocytes induced to differentiate from clone #8 in (2) above, and "A1 - B7 - #10" indicates the result of cardiomyocytes induced to differentiate from clone #10 in (3) above, and "1383D2-B2M -#1" indicates the result of cardiomyocytes induced to differentiate from the B2M knockout 1383D2 iPS cells (clone #1) described above in (4).
[0344] As a result, it was revealed that the degree of injury to cardiomyocytes induced to differentiate from 604B1 iPS cells increased when the proportion of effector CD8 positive T cells was increased.
[0345] In contrast, it was revealed that cardiomyocytes induced to differentiate from B2M knockout 1383D2 iPS cells were not damaged even when the proportion of effector CD8+ T cells was increased.Similarly, it was revealed that cardiomyocytes induced to differentiate from clones #8 and #10 in which the A*01:01 and B*07:02 alleles of 604B1 iPS cells were knocked out were not damaged even when the proportion of effector CD8+ T cells was increased.
[0346] These results indicate that by destroying the HLA alleles of iPS cells, it is possible to reduce rejection reactions when the cells are induced to differentiate and then transplanted into another host.
[0347] Furthermore, the fact that each of the iPS cells (2) to (4) above could be induced to differentiate into cardiomyocytes indicates that IFN-γ treatment can induce the expression of HLA proteins while maintaining the pluripotency of pluripotent stem cells.
[0348] [Experimental Example 24] (T cytotoxicity test 2) The iPS cells (1) to (4) in Experimental Example 23 were induced to differentiate into EB-derived blood cell-like cells. 51 Cr release assay was performed.
[0349] First, (1) 604B1 iPS cells, (2) clone #8 in which the A*01:01 allele and B*07:02 allele of 604B1 iPS cells prepared in Experimental Example 7 were knocked out, (3) clone #10 of the same, and (4) 604B1 iPS cells (clone #1) in which B2M was knocked out prepared in Experimental Example 18 were each induced to differentiate into EB-derived hemocyte-like cells. Note that EB-derived hemocyte-like cells include hemocytes.
[0350] Next, CD8 positive T cells reactive to the HLA antigen of 604B1 iPS cells prepared in Experimental Example 22 were added at various ratios to the culture medium of each EB-derived hemocyte-like cell, and it was examined whether each EB-derived hemocyte-like cell was attacked. That is, the HLA antigen-reactive CD8 T cells prepared in Experimental Example 21 were used as effector cells, and each of the above-mentioned EB-derived hemocyte-like cells was used as target cells. The ratio of the number of CD8 positive T cells added to 1 EB-derived hemocyte-like cell was 0.625, 1.25, 2.5, 5, 10, and 20.
[0351] Figure 32 is a graph showing the percentage of each EB-derived hemocyte-like cell that was injured and lysed. In Figure 32, "*" indicates a significant difference at P<0.05, "Non-edited" indicates the results for EB-derived hemocyte-like cells induced to differentiate from 604B1 iPS cells in (1) above, and "A1 - B7 - "#8" indicates the result of EB-derived blood cell-like cells induced to differentiate from clone #8 in (2) above, and "A1 - B7 - #10" indicates the result of EB-derived blood cell-like cells induced to differentiate from clone #10 in (3) above, and "604B1-B2M - #1" indicates the result of EB-derived blood cell-like cells induced to differentiate from 604B1 iPS cells (clone #1) in which B2M was knocked out as described in (4) above.
[0352] As a result, it was revealed that the degree of damage caused by EB-derived hemocyte-like cells induced to differentiate from 604B1 iPS cells increased when the proportion of effector CD8 positive T cells was increased.
[0353] In contrast, it was revealed that EB-derived hemocyte-like cells induced to differentiate from B2M-knockout 604B1 iPS cells were not damaged even when the ratio of effector CD8+ T cells was increased.Similarly, it was revealed that EB-derived hemocyte-like cells induced to differentiate from clones #8 and #10 in which the A*01:01 and B*07:02 alleles of 604B1 iPS cells were knocked out were not damaged even when the ratio of effector CD8+ T cells was increased.
[0354] These results indicate that by destroying the HLA alleles of iPS cells, it is possible to reduce rejection reactions when the cells are induced to differentiate and then transplanted into another host.
[0355] Furthermore, the fact that each of the iPS cells (2) to (4) above could be induced to differentiate into EB-derived blood cell-like cells indicates that IFN-γ treatment can induce the expression of HLA proteins while maintaining the pluripotency of pluripotent stem cells.
[0356] [Experimental Example 25] (T cytotoxicity test 3) A similar study to that of Experimental Example 24 was performed, except that different iPS cells were used. First, (1) 585A1 iPS cells having the HLA haplotypes in Table 32 below, (2) clone #2 produced in Experimental Example 9 in which the B*07:02 allele and C*07:02 allele of 585A1 iPS cells were knocked out, (3) clone #11 of the same, (4) clone #26 of the same, and (5) 604B1 iPS cells (clone #1) produced in Experimental Example 18 in which B2M was knocked out were induced to differentiate into EB-derived hemocyte-like cells. The EB-derived hemocyte-like cells include hemocytes.
[0357] [Table 32]
[0358] Next, effector CD8 positive T cells derived from peripheral blood mononuclear cells (PBMC, type number "2010113203", Wako, corresponding to the above-mentioned recipient B) having the HLA haplotypes in Table 33 below were added at various ratios to the culture medium of each EB-derived hemocyte-like cell, and it was examined whether each EB-derived hemocyte-like cell was attacked. As effector cells, CD8 positive T cells in PBMC that had become negative for CFSE, as shown in Figure 26(a) of Experimental Example 20, were sorted and used. In addition, each of the above-mentioned EB-derived hemocyte-like cells was used as the target cell. The ratio of the number of effector CD8 positive T cells added to 1 EB-derived hemocyte-like cell was 0.625, 1.25, 2.5, 5, 10, and 20.
[0359] [Table 33]
[0360] Figure 33 is a graph showing the percentage of each EB-derived hemocyte-like cell that was injured and lysed. In Figure 33, "*" indicates a significant difference at P<0.05, "Non-edited" indicates the results for EB-derived hemocyte-like cells induced to differentiate from 585A1 iPS cells in (1) above, and "B7 - C7 - #2" indicates the result of EB-derived blood cell-like cells induced to differentiate from clone #2 in (2) above, and "B7 - C7 - #11" indicates the result of EB-derived blood cell-like cells induced to differentiate from clone #11 in (3) above, and "B7 - C7 - #26" indicates the result of EB-derived blood cell-like cells induced to differentiate from clone #26 in (4) above, and "604B1-B2M - #1" indicates the result of EB-derived blood cell-like cells induced to differentiate from 604B1 iPS cells (clone #1) in which B2M was knocked out as described in (5) above.
[0361] As a result, it was revealed that the degree of damage caused by EB-derived hemocyte-like cells induced to differentiate from 585A1 iPS cells increased when the proportion of effector CD8 positive T cells was increased.
[0362] In contrast, it was revealed that EB-derived hemocyte-like cells induced to differentiate from B2M-knockout 604B1 iPS cells were not damaged even when the proportion of effector CD8+ T cells was increased.Similarly, it was revealed that EB-derived hemocyte-like cells induced to differentiate from clones #2, #11, and #26 in which the B*07:02 and C*07:02 alleles of 585A1 iPS cells were knocked out were not damaged even when the proportion of effector CD8+ T cells was increased.
[0363] These results indicate that by destroying the HLA alleles of iPS cells, it is possible to reduce rejection reactions when the cells are induced to differentiate and then transplanted into another host.
[0364] Furthermore, the fact that each of the iPS cells (2) to (5) above could be induced to differentiate into EB-derived blood cell-like cells indicates that IFN-γ treatment can induce the expression of HLA proteins while maintaining the pluripotency of pluripotent stem cells.
[0365] [Experimental Example 26] (T cytotoxicity test 4) 604B1 iPS cells having the HLA haplotype in Table 34 below, and 604B1 iPS cells (clone #1) in which B2M was knocked out, produced in Experimental Example 18, were mixed with peripheral blood mononuclear cells (PBMC, type "LP_266", CTL, corresponding to the above-mentioned recipient C) having the HLA haplotype in Table 35 below, which were labeled with CFSE (Cayman Chemical), and co-cultured for 7 days.
[0366] [Table 34]
[0367] [Table 35]
[0368] After the co-culture, flow cytometry analysis was performed to examine the fluorescence of CFSE. Figures 34(a) and (b) are graphs showing the results of flow cytometry. In Figures 34(a) and (b), "604B1-B2M - "#1" indicates the result of PBMCs co-cultured with B2M-knockout 604B1 iPS cells (clone #1), and "604B1" indicates the result of PBMCs co-cultured with 604B1 iPS cells.
[0369] As a result, as shown in FIG. 34(a), PBMCs co-cultured with B2M knockout 604B1 iPS cells (clone #1) contained 11.3% CD8 positive, CSFE negative T cells. Also, as shown in FIG. 34(b), PBMCs co-cultured with 604B1 iPS cells contained 21.3% CD8 positive, CSFE negative T cells. Next, CD8 positive, CSFE negative cells were sorted and collected as effector CD8 positive T cells from PBMCs co-cultured with 604B1 iPS cells shown in FIG. 34(b).
[0370] Next, (1) 604B1 iPS cells, (2) clone #3-11, in which the A*01:01 allele, B*37:01 allele, and C*06:02 allele of 604B1 iPS cells prepared in Experimental Example 11 were knocked out, and (3) clone #3-12 of the same were induced to differentiate into EB-derived hemocyte-like cells. The EB-derived hemocyte-like cells include hemocytes.
[0371] Next, various ratios of the collected effector CD8 positive T cells were added to the culture medium of each EB-derived hemocyte-like cell, and it was examined whether each EB-derived hemocyte-like cell was attacked. In other words, the target cells were EB-derived hemocyte-like cells induced to differentiate from each of the cells (1) to (3) above. The ratios of the effector CD8 positive T cells added to 1 EB-derived hemocyte-like cell were 0.625, 1.25, 2.5, 5, 10, and 20.
[0372] Figure 34(c) is a graph showing the percentage of each EB-derived hemocyte-like cell that was damaged and lysed. In Figure 34(c), "*" indicates a significant difference at P<0.05, "Non-edited" indicates the results for EB-derived hemocyte-like cells induced to differentiate from the 604B1 iPS cells described in (1) above, and "A1 - B37 - C6 - #3-11" indicates the result of EB-derived blood cell-like cells induced to differentiate from clone #3-11 in (2) above, and "A1 - B37 - C6 - #3-12" indicates the result of EB-derived blood cell-like cells induced to differentiate from clone #3-12 in (3) above.
[0373] As a result, it was revealed that the degree of damage caused by EB-derived hemocyte-like cells induced to differentiate from 604B1 iPS cells increased when the proportion of effector CD8 positive T cells was increased.
[0374] In contrast, it was revealed that EB-derived hemocyte-like cells induced to differentiate from clones #3-11 and #3-12, in which the A*01:01 allele, B*37:01 allele, and C*06:02 allele of 604B1 iPS cells were knocked out, were not damaged even when the proportion of effector CD8-positive T cells was increased.
[0375] These results indicate that by destroying the HLA alleles of iPS cells, it is possible to reduce rejection reactions when the cells are induced to differentiate and then transplanted into another host.
[0376] Furthermore, the fact that each of the iPS cells (2) to (3) above could be induced to differentiate into EB-derived blood cell-like cells indicates that IFN-γ treatment can induce the expression of HLA proteins while maintaining the pluripotency of pluripotent stem cells.
[0377] [Experimental Example 27] (NK cell reactivity test 1) (1) 604B1 iPS cells having the HLA haplotype in Table 36 below, (2) clone #8 in which the A*01:01 allele and B*07:02 allele of 604B1 iPS cells were knocked out, (3) clone #10, (4) 1383D2 iPS cells having the HLA haplotype in Table 37 below, and (5) 604B1 iPS cells (clone #1) in which B2M was knocked out, prepared in Experimental Example 18, were differentiated into EB-derived blood cell-like cells. The EB-derived blood cell-like cells include CD45-positive white blood cells.
[0378] [Table 36]
[0379] [Table 37]
[0380] In addition, CD56 positive cells (NK cells) were collected by sorting from PBMCs (type "LP_194", CTL, Inc., corresponding to the above-mentioned recipient A) having the HLA haplotype in Table 38 below. Next, the collected NK cells were co-cultured with each of the differentiated CD45 positive leukocytes in the presence of an anti-CD107a antibody. As a result, when the NK cells are activated, they become CD107a positive. After the co-culture, flow cytometry analysis was performed to measure the proportion of activated NK cells.
[0381] [Table 38]
[0382] 35(a)-(g) are graphs showing the results of flow cytometry analysis. FIG. 35(a) shows the results of analysis of NK cells cultured alone. FIG. 35(b) shows the results of analysis of NK cells co-cultured with EB-derived hemocyte-like cells induced to differentiate from 604B1 iPS cells. FIG. 35(c) shows the results of analysis of NK cells co-cultured with EB-derived hemocyte-like cells induced to differentiate from clone #8 in which the A*01:01 allele and B*07:02 allele of 604B1 iPS cells were knocked out. FIG. 35(d) shows the results of analysis of NK cells co-cultured with EB-derived hemocyte-like cells induced to differentiate from the same clone #10. FIG. 35(e) shows the results of analysis of NK cells co-cultured with EB-derived hemocyte-like cells induced to differentiate from 1383D2 iPS cells. FIG. 35(f) shows the results of analysis of NK cells co-cultured with EB-derived hemocyte-like cells induced to differentiate from 604B1 iPS cells in which B2M was knocked out. FIG. 35(g) shows the results of analyzing NK cells co-cultured with K562 cells, which are known not to express HLA antigens, as a positive control.
[0383] As a result, it was found that 5.9% of NK cells co-cultured with K562 cells were activated, and 3.2% of NK cells co-cultured with EB-derived hemocyte-like cells induced to differentiate from B2M knockout 604B1 iPS cells, which do not express HLA antigens, were activated.
[0384] In contrast, in clones #8 and #10, in which the A*01:01 and B*07:02 alleles of 604B1 iPS cells were knocked out, expression of the other A*24:02 and B*37:01 alleles remained, and it was revealed that activation of NK cells co-cultured with EB-derived hemocyte-like cells induced to differentiate from these clones was suppressed.
[0385] In other words, it was revealed that cells in which B2M was knocked out were significantly attacked by NK cells, whereas cells in which some HLA alleles remained were able to avoid attack by NK cells.
[0386] [Experimental Example 28] (Pluripotency Confirmation Test 1) For 1383D2 iPS cells and 604B1 iPS cells, (1) untreated, (2) immediately after 48 hours of treatment with 50 ng / mL IFN-γ, and (3) 5 days after 48 hours of treatment with 50 ng / mL IFN-γ, each cell was prepared and mRNA was extracted. Next, cDNA was synthesized using Rever Tra Ase qPCR RT Master Mix (Toyobo), and quantitative PCR was performed using primers that amplify human NANOG cDNA, which is specifically expressed in pluripotent stem cells, and primers that amplify human ACTB cDNA as a control for the total amount of mRNA.
[0387] The primers used for amplifying human NANOG cDNA and the primers used for amplifying human ACTB cDNA are shown in Table 39 below.
[0388] [Table 39]
[0389] 36 is a graph showing the results of quantitative PCR in which the expression level of the NANOG gene was measured. The expression level of the NANOG gene is shown as a relative value, with the expression level of the NANOG gene relative to the ACTB gene in “untreated” 1383D2 cells being set at 1.
[0390] In Figure 36, "Untreated" indicates the result for iPS cells cultured under normal undifferentiation maintenance conditions without treatment with IFN-γ, "Immediately after IFN" indicates the result for cells immediately after treatment with IFN-γ for 48 hours, and "5 days later" indicates the result for cells 5 days after treatment with IFN-γ for 48 hours.
[0391] As a result, it was revealed that the expression level of NANOG, which is widely used as a pluripotency marker, did not decrease even when iPS cells were treated with IFN-γ for 48 hours, indicating that pluripotency is maintained even when iPS cells are treated with IFN-γ.
[0392] [Experimental Example 29] (Pluripotency confirmation test 2) (1) 604B1 iPS cells, (2) clone #3-11 in which the A*01:01 allele, B*37:01 allele, and C*06:02 allele of 604B1 iPS cells prepared in Experimental Example 11 were disrupted, (3) clone #3-12 of the same, (4) clone #1 in which the B2M gene of 604B1 iPS cells prepared in Experimental Example 18 was disrupted, (5) 1383D2 iPS cells, and (6) clone #1 in which the B2M gene of 1383D2 iPS cells prepared in Experimental Example 17 was disrupted, were cultured under conditions for maintaining undifferentiation, and the morphology of each cell was observed under a phase-contrast microscope.
[0393] Culture under undifferentiated maintenance conditions was performed using AK03N medium (StemFit, Ajinomoto) as the medium and "iMatrix-511" (Nippi) as the cell matrix.
[0394] 37(a) to (f) are photographs of the above cells (1) to (5) taken with a phase-contrast microscope, respectively. The scale bar is 1 mm.
[0395] As a result, it was found that iPS cells that had been treated with IFN-γ after HLA or B2M allele destruction also formed flat colonies characteristic of undifferentiated pluripotent stem cells and proliferated. This result indicates that pluripotency is maintained even when iPS cells are treated with IFN-γ. This result also indicates that pluripotency is maintained even when iPS cells have HLA or B2M allele destruction.
[0396] [Experimental Example 30] (Pluripotency Confirmation Test 3) (1) 604B1 iPS cells, (2) clone #3-11 in which the A*01:01 allele, B*37:01 allele, and C*06:02 allele of 604B1 iPS cells prepared in Experimental Example 11 were disrupted, (3) clone #3-12 of the same, (4) clone #1 in which the B2M gene of 604B1 iPS cells prepared in Experimental Example 18 was disrupted, (5) 1383D2 iPS cells, and (6) clone #1 in which the B2M gene of 1383D2 iPS cells prepared in Experimental Example 17 was disrupted, were each cultured under blood cell differentiation-inducing conditions, and the morphology of EB-derived blood cell-like cells was observed using a phase-contrast microscope.
[0397] iPS cells were induced to differentiate into blood cells as follows: First, undifferentiated iPS cells were seeded on ultra-low attachment culture plates (Corning) and EBs (embryoid bodies) were formed in AK03N medium containing Y-27633 for 2 days. Then, the cells were cultured for an additional 3 days in StemPro-34 SFM medium (Thermo Fisher Scientific) containing human bFGF (Oriental Yeast), human VEGF (R&D Systems), ITS (insulin-transferrin-selenium, Thermo Fisher Scientific), GlutaMax-I (Thermo Fisher Scientific), L-ascorbic acid 2-phosphate sesquimagnesium salt hydrate (Sigma), 1-thioglycerol (MTG, Nacalai Tesque), and human BMP4 (R&D Systems). After that, human BMP4 was removed, human SCF was added, and the cells were cultured for 2 days. Subsequently, human Flt3-Ligand (Peprotech) and human TPO (Peprotech) were added and cultured, resulting in the generation of EB-derived blood cell-like cells.
[0398] 38(a) to (f) are photographs taken with a phase contrast microscope of the EB-derived blood cell-like cells of each of (1) to (5) above on day 22 after differentiation induction. The scale bar is 1 mm.
[0399] As a result, it was revealed that iPS cells that had been treated with IFN-γ after HLA or B2M allele destruction could be induced to differentiate into blood cell-like cells. This result indicates that pluripotency is maintained even when iPS cells are treated with IFN-γ. This result also indicates that pluripotency is maintained even when HLA or B2M alleles of iPS cells are destroyed.
[0400] [Experimental Example 31] (T cytotoxicity test 5) (1) 1383D2 iPS cells (clone #1) having the B2M allele knocked out and having the HLA haplotype shown in Table 40 below, prepared in Experimental Example 17, and (2) 585A1 iPS cells having the HLA haplotype shown in Table 41 below, were stained with CFSE (Cayman Chemical Company) and co-cultured for 7 days with peripheral blood mononuclear cells (PBMC, type "LP_275", CTL Corporation) having the HLA haplotype shown in Table 42 below.
[0401] [Table 40]
[0402] [Table 41]
[0403] [Table 42]
[0404] After co-culture, flow cytometry analysis was performed to examine CFSE fluorescence. Figures 39(a) and (b) are graphs showing the results of flow cytometry. In Figures 39(a) and (b), "1383D2 B2M-KO#1" shows the results of PBMCs co-cultured with 1383D2 iPS cells (clone #1) in which B2M was knocked out, and "585A1-WT" shows the results of PBMCs co-cultured with 585A1 iPS cells.
[0405] As a result, as shown in Figure 39(a), PBMCs co-cultured with B2M knockout 1383D2 iPS cells (clone #1) did not contain CD8 positive, CSFE negative T cells. Also, as shown in Figure 39(b), PBMCs co-cultured with 585A1 iPS cells contained 24.4% CD8 positive T cells that had been activated and turned CSFE negative. Next, CD8 positive and CSFE negative cells were sorted and collected as effector CD8 positive T cells from PBMCs co-cultured with 585A1 iPS cells, as shown in Figure 39(b).
[0406] Next, (1) 585A1 iPS cells, (2) clone #3-1, (3) clone #3-3, (4) 585A1 iPS cell clone (prepared in Experimental Example 13) in which the A*24:02 allele, B*07:02 allele, B*52:01 allele, and C*12:02 allele were knocked out, and (5) 585A1 iPS cell clone (bulk cells not subcloned) in which the B2M allele was knocked out, and (6) 585A1 iPS cell clone (prepared in Experimental Example 46) were differentiated into EB-derived hemocyte-like cells. Note that EB-derived hemocyte-like cells include hemocytes.
[0407] Next, various ratios of the collected effector CD8 positive T cells were added to the culture medium of each EB-derived hemocyte-like cell, and it was examined whether each EB-derived hemocyte-like cell was attacked. In other words, the target cells were EB-derived hemocyte-like cells induced to differentiate from each of the cells (1) to (4) above. The ratios of the number of effector CD8 positive T cells added to 1 EB-derived hemocyte-like cell were 0.625, 1.25, 2.5, 5, 10, and 20.
[0408] Figure 39(c) is a graph showing the percentage of each EB-derived hemocyte-like cell that was damaged and lysed. In Figure 39(c), "**" indicates a significant difference at P<0.01, "WT" indicates the results for EB-derived hemocyte-like cells induced to differentiate from 585A1 iPS cells in (1) above, "C7#3-1" indicates the results for EB-derived hemocyte-like cells induced to differentiate from clone #3-1 in (2) above, "C7#3-3" indicates the results for EB-derived hemocyte-like cells induced to differentiate from clone #3-3 in (3) above, and "B2M - " indicates the result of EB-derived blood cell-like cells induced to differentiate from cells in which the B2M allele of the 585A1 iPS cells described above in (4) was knocked out.
[0409] As a result, it was revealed that the degree of damage caused by EB-derived hemocyte-like cells induced to differentiate from 585A1 iPS cells increased when the proportion of effector CD8 positive T cells was increased.
[0410] In contrast, it was demonstrated that EB-derived hemocyte-like cells induced to differentiate from clones #3-1 and #3-3, in which the A*24:02 allele, B*07:02 allele, B*52:01 allele, and C*12:02 allele were knocked out in 585A1 iPS cells, and EB-derived hemocyte-like cells induced to differentiate from cells in which the B2M allele was knocked out in 585A1 iPS cells, were not damaged even when the proportion of effector CD8-positive T cells was increased.
[0411] These results further support the idea that disrupting the HLA alleles of iPS cells can reduce rejection reactions when they are induced to differentiate and then transplanted into another host.
[0412] [Experimental Example 32] (T cytotoxicity test 6) (1) 1383D2 iPS cells (clone #1) having the B2M allele knocked out and having the HLA haplotype in Table 43 below, prepared in Experimental Example 17, and (2) 585A1 iPS cells having the HLA haplotype in Table 44 below, were co-cultured for 7 days with peripheral blood mononuclear cells (PBMC, type "LP_329", CTL) having the HLA haplotype in Table 45 below, stained with CFSE (Cayman Chemical).
[0413] [Table 43]
[0414] [Table 44]
[0415] [Table 45]
[0416] After co-culture, flow cytometry analysis was performed to examine CFSE fluorescence. Figures 40(a) and (b) are graphs showing the results of flow cytometry. In Figures 40(a) and (b), "1383D2 B2M-KO#1" shows the results of PBMCs co-cultured with 1383D2 iPS cells (clone #1) in which B2M was knocked out, and "585A1-WT" shows the results of PBMCs co-cultured with 585A1 iPS cells.
[0417] As a result, as shown in Figure 40(a), PBMCs co-cultured with B2M knockout 1383D2 iPS cells (clone #1) did not contain CD8 positive, CSFE negative T cells. Also, as shown in Figure 40(b), PBMCs co-cultured with 585A1 iPS cells contained 11.7% CD8 positive T cells that had been activated and become CSFE negative. Next, CD8 positive and CSFE negative cells were sorted and collected as effector CD8 positive T cells from PBMCs co-cultured with 585A1 iPS cells, as shown in Figure 40(b).
[0418] Next, (1) 585A1 iPS cells, (2) clone #3-1, (3) clone #3-3, (4) 585A1 iPS cell clone (prepared in Experimental Example 13) in which the A*24:02 allele, B*07:02 allele, B*52:01 allele, and C*12:02 allele were knocked out, and (5) 585A1 iPS cell clone (bulk cells not subcloned) in which the B2M allele was knocked out, and (6) 585A1 iPS cell clone (prepared in Experimental Example 46) were differentiated into EB-derived hemocyte-like cells. Note that EB-derived hemocyte-like cells include hemocytes.
[0419] Next, various ratios of the collected effector CD8 positive T cells were added to the culture medium of each EB-derived hemocyte-like cell, and it was examined whether each EB-derived hemocyte-like cell was attacked. In other words, the target cells were EB-derived hemocyte-like cells induced to differentiate from each of the cells (1) to (4) above. The ratios of the number of effector CD8 positive T cells added to 1 EB-derived hemocyte-like cell were 0.625, 1.25, 2.5, 5, 10, and 20.
[0420] Figure 40(c) is a graph showing the percentage of each EB-derived hemocyte-like cell that was damaged and lysed. In Figure 40(c), "**" indicates a significant difference at P<0.01, "WT" indicates the results for EB-derived hemocyte-like cells induced to differentiate from 585A1 iPS cells in (1) above, "C7#3-1" indicates the results for EB-derived hemocyte-like cells induced to differentiate from clone #3-1 in (2) above, "C7#3-3" indicates the results for EB-derived hemocyte-like cells induced to differentiate from clone #3-3 in (3) above, and "B2M - " indicates the result of EB-derived blood cell-like cells induced to differentiate from cells in which the B2M allele of the 585A1 iPS cells described above in (4) was knocked out.
[0421] As a result, it was revealed that the degree of damage caused by EB-derived hemocyte-like cells induced to differentiate from 585A1 iPS cells increased when the proportion of effector CD8 positive T cells was increased.
[0422] In contrast, it was demonstrated that EB-derived hemocyte-like cells induced to differentiate from clones #3-1 and #3-3 in which the A*24:02 allele, B*07:02 allele, B*52:01 allele, and C*12:02 allele were knocked out in 585A1 iPS cells, and EB-derived hemocyte-like cells induced to differentiate from 1383D2 iPS cells in which the B2M allele was knocked out were not damaged even when the proportion of effector CD8-positive T cells was increased.
[0423] These results further support the idea that disrupting the HLA alleles of iPS cells can reduce rejection reactions when they are induced to differentiate and then transplanted into another host.
[0424] [Experimental Example 33] (Cell transplantation experiment 1) (1) 585A1 iPS cells, and (2) clone #3-1, which was generated in Experimental Example 13 by knocking out the A*24:02 allele, B*07:02 allele, B*52:01 allele, and C*12:02 allele of 585A1 iPS cells, were induced to differentiate into EB-derived hemocyte-like cells. Then, each EB-derived hemocyte-like cell was labeled with luciferase.
[0425] Next, 1 hour before the start of the experiment, immunodeficient mice (NOD.Cg-Rag1 tm1Mom Il2rg tm1Wjl Each cell type was transplanted into mice (N = 10 / SzJ (NRG), The Jackson Laboratory) using the same method as in Experimental Example 32. At the start of the experiment, effector CD8-positive T cells derived from peripheral blood mononuclear cells (PBMC, type "LP_329", CTL) or a medium (control) prepared in the same manner as in Experimental Example 32 were further intraperitoneally administered.
[0426] Next, at the time of cell transplantation (before T cell injection), and 5 hours, 1 day, 3 days, and 7 days after the start of the experiment, each mouse was administered luciferin, a substrate of luciferase, and the fluorescence of the luciferase-labeled EB-derived blood cell-like cells was photographed using an IVIS imaging system (product name "IVIS Spectrum", SPI Corporation) to measure the survival rate of the transplanted cells.
[0427] Figure 41(a) is a diagram explaining the experimental schedule. Figure 41(b) is a photograph showing the results of photographing the fluorescence of EB-derived hemocyte-like cells in each mouse. Figure 41(c) is a graph of a relative survival curve showing the results of calculating the survival rate of each EB-derived hemocyte-like cell when effector CD8-positive T cells were administered to a mouse, with the fluorescence intensity before T cell injection set at 100%.
[0428] In Figures 41(b) and (c), "WT" indicates the result of EB-derived blood cell-like cells induced to differentiate from the 585A1 iPS cells described above in (1), "C7#3-1" indicates the result of EB-derived blood cell-like cells induced to differentiate from the clone #3-1 described above in (2), "Mock" indicates the result of administering culture medium as a control, and "T cells" indicates the result of administering effector CD8-positive T cells derived from peripheral blood mononuclear cells (PBMC, type "LP_329", CTL Corporation).
[0429] As a result, as shown in Figure 41 (c), it was confirmed that the survival rate of EB-derived hemocyte-like cells induced to differentiate from 585A1 iPS cells was reduced after administration of effector CD8-positive T cells. In contrast, it was revealed that EB-derived hemocyte-like cells induced to differentiate from clone #3-1, in which the A*24:02 allele, B*07:02 allele, B*52:01 allele, and C*12:02 allele of 585A1 iPS cells were knocked out, maintained a high survival rate even after administration of effector CD8-positive T cells.
[0430] These results further support the idea that disrupting the HLA alleles of iPS cells can reduce rejection reactions when they are induced to differentiate and then transplanted into another host.
[0431] [Experimental Example 34] (NK cell reactivity test 2) (1) 585A1 iPS cells, (2) clone #3-1 produced in Experimental Example 13 in which the A*24:02 allele, B*07:02 allele, B*52:01 allele, and C*12:02 allele of 585A1 iPS cells were knocked out, and (3) cells (bulk cells not subcloned) produced in Experimental Example 46 described below in which the B2M allele of 585A1 iPS cells was knocked out were prepared. Table 46 below shows the HLA haplotypes of 585A1 iPS cells, and Table 47 below shows the HLA haplotypes of 1383D2 iPS cells. [Table 46]
[0432] [Table 47]
[0433] In addition, CD56 positive cells (NK cells) were collected by sorting from PBMCs (type "LP_275", CTL) having the HLA haplotypes in Table 48 below. The collected NK cells were then co-cultured with each of the above-mentioned cells (1) to (3) in the presence of an anti-CD107a antibody. As a result, the NK cells became CD107a positive when activated. After the co-culture, flow cytometry analysis was performed to measure the proportion of activated NK cells.
[0434] [Table 48]
[0435] Figure 42(a) is a graph showing the results of flow cytometry analysis. In Figure 42(a), "**" indicates a significant difference at P<0.01, "WT" indicates the results for 585A1 iPS cells in (1) above, "C7#3-1" indicates the results for clone #3-1 in (2) above, and "B2M- " indicates the result of cells in which the B2M allele was knocked out in the 585A1 iPS cells (3) above.
[0436] As a result, it was revealed that NK cell activation was significantly suppressed in 585A1 iPS cells and clone #3-1 compared to cells in which the B2M allele was knocked out. Next, NK cells activated in the cells in which the B2M allele was knocked out were sorted and collected.
[0437] Next, (4) K562 cells known not to express HLA antigens, (5) cells (bulk cells not subcloned) in which the B2M allele of 585A1 iPS cells was knocked out, prepared in Experimental Example 46 described below, (6) cells (clone #3-5, HLA-E, F, G alleles remain) in which the HLA-A allele, HLA-B allele, and HLA-C allele of 585A1 iPS cells was knocked out, prepared in Experimental Example 47 described below, (7) clone #3-1 in which the A*24:02 allele, B*07:02 allele, B*52:01 allele, and C*12:02 allele of 585A1 iPS cells was knocked out, prepared in Experimental Example 13, (8) clone #3-3, (9) 585A1 iPS cells prepared in Experimental Example 13, iPS cells with HLA-A and HLA-B alleles knocked out (clone #3, HLA-C, E, F, G alleles remain), (10) 585A1 iPS cells were added with activated NK cells at various ratios. 51 Cr release assay was performed.
[0438] That is, the above-mentioned activated NK cells were used as effector cells, and the above-mentioned cells (4) to (10) were used as target cells. The ratio of the number of NK cells to the number of target cells was 1:0.33, 1, and 3.
[0439] FIG. 42(b) is a graph showing the percentage of cells injured and lysed in each of the above (4) to (10). In FIG. 42(b), "*" indicates a significant difference at P<0.05, "**" indicates a significant difference at P<0.01, "K562" indicates the results for the K562 cells in (4) above, and "B2M - " indicates the result of knockout of the B2M allele in the 585A1 iPS cells mentioned above (5), and "A - B - C - "C7#3-1" indicates the results of clone #3-1 in (7) above, "C7#3-3" indicates the results of clone #3-3 in (8) above, and "A7#3-4" indicates the results of clone #3-4 in (9) above. - B - "#3" indicates the results for the cells (clone #3) in which the HLA-A allele and the HLA-B allele were knocked out as described above in (9), and "585A1-WT" indicates the results for the 585A1 iPS cells as described above in (10).
[0440] As a result, it was revealed that cells that retained the HLA-C allele were able to significantly avoid attack by NK cells compared to cells in which B2M was knocked out and cells in which the HLA-A, HLA-B and HLA-C alleles were knocked out.
[0441] [Experimental Example 35] (NK cell reactivity test 3) (1) 585A1 iPS cells, (2) clone #3-1 produced in Experimental Example 13 in which the A*24:02 allele, B*07:02 allele, B*52:01 allele, and C*12:02 allele of 585A1 iPS cells were knocked out, and (3) cells (bulk cells not subcloned) produced in Experimental Example 46 described below in which the B2M allele of 585A1 iPS cells was knocked out were prepared. Table 49 below shows the HLA haplotypes of 585A1 iPS cells, and Table 50 below shows the HLA haplotypes of 1383D2 iPS cells. [Table 49]
[0442] [Table 50]
[0443] In addition, CD3 negative CD56 positive cells (NK cells) were collected by sorting from PBMCs (type "LP_329", CTL) having the HLA haplotypes in Table 51 below. The collected NK cells were then co-cultured with each of the cells (1) to (3) above in the presence of an anti-CD107a antibody. As a result, the NK cells became CD107a positive when activated. After the co-culture, flow cytometry analysis was performed to measure the proportion of activated NK cells.
[0444] [Table 51]
[0445] Figure 43(a) is a graph showing the results of flow cytometry analysis. In Figure 43(a), "**" indicates a significant difference at P<0.01, "WT" indicates the results for 585A1 iPS cells in (1) above, "C7#3-1" indicates the results for clone #3-1 in (2) above, and "B2M - " indicates the result of cells in which the B2M allele was knocked out in the 585A1 iPS cells (3) above.
[0446] As a result, it was revealed that NK cell activation was significantly suppressed in 585A1 iPS cells and clone #3-1 compared to cells in which the B2M allele was knocked out. Next, NK cells activated in the cells in which the B2M allele was knocked out were sorted and collected.
[0447] Next, (4) K562 cells known not to express HLA antigens, (5) cells (bulk cells not subcloned) in which the B2M allele of 585A1 iPS cells was knocked out, prepared in Experimental Example 46 described below, (6) cells (clone #3-5, HLA-E, F, G alleles remain) in which the HLA-A allele, HLA-B allele, and HLA-C allele of 585A1 iPS cells was knocked out, prepared in Experimental Example 47 described below, (7) clone #3-1 in which the A*24:02 allele, B*07:02 allele, B*52:01 allele, and C*12:02 allele of 585A1 iPS cells was knocked out, prepared in Experimental Example 13, (8) clone #3-3, (9) 585A1 iPS cells prepared in Experimental Example 13, iPS cells with HLA-A and HLA-B alleles knocked out (clone #3, HLA-C, E, F, G alleles remain), (10) 585A1 iPS cells were added with activated NK cells at various ratios. 51 Cr release assay was performed.
[0448] That is, the above-mentioned activated NK cells were used as effector cells, and the above-mentioned cells (4) to (10) were used as target cells. The ratio of the number of NK cells to the number of target cells was 1:0.33, 1, and 3.
[0449] FIG. 43(b) is a graph showing the percentage of cells injured and lysed in each of the above (4) to (10). In FIG. 43(b), "**" indicates a significant difference at P<0.01, "K562" indicates the results for the K562 cells in (4) above, and "B2M - " indicates the result of knockout of the B2M allele in the 585A1 iPS cells mentioned above (5), and "A - B - C -"C7#3-1" indicates the results of clone #3-1 in (7) above, "C7#3-3" indicates the results of clone #3-3 in (8) above, and "A7#3-4" indicates the results of clone #3-4 in (9) above. - B - "#3" indicates the results for the cells (clone #3) in which the HLA-A allele and the HLA-B allele were knocked out as described above in (9), and "585A1-WT" indicates the results for the 585A1 iPS cells as described above in (10).
[0450] As a result, it was revealed that cells that retained the HLA-C allele were able to significantly avoid attack by NK cells compared to cells in which B2M was knocked out and cells in which the HLA-A, HLA-B and HLA-C alleles were knocked out.
[0451] [Experimental Example 36] (NK cell reactivity test 4) (1) 585A1 iPS cells, (2) clone #3-1 produced in Experimental Example 13 in which the A*24:02 allele, B*07:02 allele, B*52:01 allele, and C*12:02 allele of 585A1 iPS cells were knocked out, (3) cells produced in Experimental Example 46 described below in which the B2M allele of 585A1 iPS cells was knocked out (bulk cells that were not subcloned), and (4) K562 cells known not to express HLA antigens were prepared. Table 52 below shows the HLA haplotypes of 585A1 iPS cells, and Table 53 below shows the HLA haplotypes of 1383D2 iPS cells. [Table 52]
[0452] [Table 53]
[0453] In addition, CD3 negative CD56 positive cells (NK cells) were collected by sorting from PBMCs (type "LP_118", CTL) having the HLA haplotype in Table 54 below and PBMCs (type "LP_266", CTL) having the HLA haplotype in Table 55 below. The collected NK cells were then co-cultured with each of the cells (1) to (4) above in the presence of an anti-CD107a antibody. As a result, the NK cells became CD107a positive when activated. After the co-culture, flow cytometry analysis was performed to measure the proportion of activated NK cells.
[0454] [Table 54]
[0455] [Table 55]
[0456] Figures 44(a) and (b) are graphs showing the results of flow cytometry analysis. Figure 44(a) shows the results for NK cells derived from PBMC (type "LP_118", CTL) having the HLA haplotype in Table 54 above, and Figure 44(b) shows the results for NK cells derived from PBMC (type "LP_266", CTL) having the HLA haplotype in Table 55 above. In Figures 44(a) and (b), "**" indicates a significant difference at P<0.01, "WT" indicates the results for 585A1 iPS cells in (1) above, "C7#3-1" indicates the results for clone #3-1 in (2) above, and "B2M - " indicates the results for cells in which the B2M allele was knocked out in the 585A1 iPS cells described above in (3), and "K562" indicates the results for the K562 cells described above in (4).
[0457] As a result, it was revealed that NK cell activation was significantly suppressed in 585A1 iPS cells and clone #3-1, compared with cells in which the B2M allele was knocked out.
[0458] [Experimental Example 37] (Cell transplantation experiment 2) (1) 585A1 iPS cells with the B2M gene knocked out, and (2) clone #3-1, 585A1 iPS cells with the A*24:02 allele, B*07:02 allele, B*52:01 allele, and C*12:02 allele knocked out, prepared in Experimental Example 13, were each induced to differentiate into EB-derived hemocyte-like cells. Then, each EB-derived hemocyte-like cell was labeled with luciferase.
[0459] Next, 1 hour before the start of the experiment, immunodeficient mice (NOD.Cg-Rag1 tm1Mom Il2rg tm1Wjl Each cell type was transplanted into mouse bronchodilators (Neuroptera bronchiseptica, Breast Cancer Respiratory Care (CRC) mice ...) (Neuroptera bronchiseptica, Breast Cancer Respiratory Care (CRC) mice). At the start of the experiment, activated NK cells derived from peripheral blood mononuclear cells (PBMC, type "LP_329", CTL) or a medium (control) prepared in the same manner as in Experimental Examples 34 and 35 were further intraperitoneally administered. The HLA haplotypes of PBMC (type "LP_329", CTL) are shown in Table 56 below.
[0460] [Table 56]
[0461] Next, at the time of cell transplantation (before NK cell injection), and 5 hours, 1 day, 3 days, 5 days, and 7 days after the start of the experiment, each mouse was administered luciferin, a substrate for luciferase, and the fluorescence of the luciferase-labeled EB-derived blood cell-like cells was photographed using an IVIS imaging system (product name "IVIS Spectrum", SPI Corporation) to measure the survival rate of the transplanted cells.
[0462] Figure 45(a) is a diagram explaining the experimental schedule. Figure 45(b) is a photograph showing the results of photographing the fluorescence of EB-derived blood cell-like cells in each mouse. Figure 45(c) is a graph showing the results of calculating the survival rate of each EB-derived blood cell-like cell when NK cells were administered to a mouse, with the fluorescence intensity before NK cell injection set at 100%, and further calculating the relative survival rate at each measurement time using the following formula (F1). In Figure 45(c), the vertical axis is in %. Relative survival rate (%) = survival rate (%) of NK cell-administered group / survival rate (%) of control group × 100 ... (F1)
[0463] In Figure 45(b) and (c), "B2M - " indicates the result of EB-derived blood cell-like cells induced to differentiate from cells in which the B2M gene was knocked out of the 585A1 iPS cells described above in (1); "C7#3-1" indicates the result of EB-derived blood cell-like cells induced to differentiate from clone #3-1 described above in (2); "Mock" indicates the result of administering culture medium as a control; and "NK cells" indicates the result of administering activated NK cells derived from peripheral blood mononuclear cells (PBMC, type "LP_329", CTL Corporation).
[0464] As a result, as shown in Figure 45(c), it was confirmed that the survival rate of EB-derived hemocyte-like cells induced to differentiate from B2M gene knockout cells was reduced after administration of NK cells. In contrast, the survival rate of EB-derived hemocyte-like cells induced to differentiate from clone #3-1 tended to be higher even after administration of activated NK cells.
[0465] These results further support the idea that maintaining some HLA alleles can reduce attack by NK cells in allogeneic transplants.
[0466] [Experimental Example 38] (T cell and NK cell cytotoxicity test) (1) 585A1 iPS cells, (2) clone #3-1, in which the A*24:02 allele, B*07:02 allele, B*52:01 allele, and C*12:02 allele of 585A1 iPS cells prepared in Experimental Example 13 were knocked out, and (3) cells in which the B2M allele of 585A1 iPS cells (bulk cells that were not subcloned), prepared in Experimental Example 46 described below, were each induced to differentiate into EB-derived blood cell-like cells.
[0467] Next, effector CD8-positive T cells sorted and collected from peripheral blood mononuclear cells (PBMC, model number "LP_275", CTL) in the same manner as in Experimental Example 31, and activated NK cells sorted and collected from PBMC (model number "LP_275", CTL) in the same manner as in Experimental Example 34 were added at various ratios to the medium of each EB-derived hemocyte-like cell. 51 Cr release assay was performed.
[0468] That is, the target cells were EB-derived hemocyte-like cells induced to differentiate from each of the above cells (1) to (3), and the effector cells were the above-mentioned CD8-positive T cells and activated NK cells. The ratio of the number of effector CD8-positive T cells to 1 part of EB-derived hemocyte-like cells was 1, 3, or 9. The ratio of the number of activated NK cells to 1 part of EB-derived hemocyte-like cells was 0.33, 1, or 3.
[0469] Figure 46 is a graph showing the percentage of each EB-derived hemocyte-like cell that was injured and lysed. In Figure 46, "*" indicates a significant difference at P<0.05, "**" indicates a significant difference at P<0.01, "WT" indicates the results for EB-derived hemocyte-like cells induced to differentiate from 585A1 iPS cells in (1) above, "C7#3-1" indicates the results for EB-derived hemocyte-like cells induced to differentiate from clone #3-1 in (2) above, and "B2M - " indicates the result of EB-derived blood cell-like cells induced to differentiate from cells in which the B2M allele of the 585A1 iPS cells described above in (3) was knocked out.
[0470] As a result, it was confirmed that when each EB-derived hemocyte-like cell was mixed with effector CD8-positive T cells alone, only the EB-derived hemocyte-like cells induced to differentiate from 585A1 iPS cells were damaged.
[0471] Furthermore, when activated NK cells were mixed with each EB-derived hemocyte-like cell alone, it was confirmed that only the EB-derived hemocyte-like cells induced to differentiate from cells in which the B2M allele had been knocked out were damaged.
[0472] Furthermore, when each EB-derived hemocyte-like cell was mixed with both effector CD8-positive T cells and activated NK cells, both EB-derived hemocyte-like cells induced to differentiate from 585A1 iPS cells and EB-derived hemocyte-like cells induced to differentiate from cells in which the B2M allele had been knocked out were damaged, but the degree of damage to EB-derived hemocyte-like cells induced to differentiate from C7#3-1 cells was significantly suppressed.
[0473] These results indicate that by destroying HLA alleles present in donor cells but not in recipient cells, and leaving HLA alleles that match between donor and recipient cells, it is possible to reduce the damage caused by both effector CD8+ T cells and activated NK cells.
[0474] [Experimental Example 39] (Creation of CIITA gene knockout iPS cells) The CIITA gene encodes the Class II Major Histocompatibility Complex Transactivator protein. As mentioned above, expression of the CIITA gene is known to be essential for the expression of class II HLA proteins.
[0475] The CIITA gene was knocked out in clone #3-1 (hereinafter sometimes referred to as "585A1-C7 remaining cells"), which was prepared in Experimental Example 13 by knocking out the A*24:02 allele, B*07:02 allele, B*52:01 allele, and C*12:02 allele of 585A1 iPS cells.
[0476] 47(a) is a table showing the HLA haplotypes of 585A1-C7 remaining cells and 585A1-C7 remaining cells in which the CIITA gene has been knocked out. By knocking out the CIITA gene, it is possible to eliminate class II HLA proteins such as HLA-DP, HLA-DQ, and HLA-DR.
[0477] Specifically, 585A1-C7 remaining cells were transfected with CIITA-ex3g5 (target nucleotide sequence shown in SEQ ID NO: 8017), an sgRNA that cleaves the CIITA allele, together with purified Cas9 protein, to obtain 28 subclones. Transfection was performed using a commercially available kit (product name "4D-Nucleofector", model number "V4XP-4032", Lonza).
[0478] Next, the genomic base sequence of the CIITA allele of each subclone was analyzed. Figure 47(b) shows the base mutation pattern of each subclone. In Figure 47(b), "Clone ID" indicates the name of the subclone, "WT" indicates that the base sequence was of the wild type, "-" indicates that the subclone had a deletion mutation, and "+" indicates that the subclone had an insertion mutation.
[0479] As a result, as shown in Figure 47(b), it was confirmed that deletion or insertion mutations were introduced into at least one CIITA allele in 15 of the 28 subclones. Figure 47(c) shows the base sequence of clone #3-1-3 as a representative example.
[0480] [Experimental Example 40] (CD4 positive T cell activation test) CD4 positive T cells were collected by sorting from peripheral blood mononuclear cells (PBMCs) derived from healthy volunteer #21, and stained with CFSE (Cayman Chemical).
[0481] Next, the above CD4 positive T cells were mixed with (1) 585A1 iPS cells, (2) clone #3-1 (hereinafter sometimes referred to as "585A1-C7 remaining cells") prepared in Experimental Example 13 in which the A*24:02 allele, B*07:02 allele, B*52:01 allele, and C*12:02 allele of 585A1 iPS cells were knocked out, and (3) cells (clone #3-1-3) prepared in Experimental Example 39 in which the CIITA gene of 585A1-C7 remaining cells was knocked out, and co-cultured for one week. In addition, for comparison, (4) a group in which only the above CD4 positive T cells were cultured alone for one week was also prepared.
[0482] After co-culture, flow cytometry analysis was performed to examine CFSE fluorescence. Figure 48 (a) to (d) are graphs showing the results of flow cytometry. In Figure 48 (a) to (d), "Mock" indicates the result of culturing only the CD4-positive T cells alone (4) above, "585A1-WT" indicates the result of culturing the 585A1 iPS cells (1) above, "585A1-C7#3-1" indicates the result of culturing the 585A1-C7 remaining cells (2) above, and "585A1-C7+CIITA - #3-1-3" indicates the result for cells (clone #3-1-3) in which the CIITA gene was knocked out from the 585A1-C7 remaining cells in (3) above.
[0483] As a result, as shown in FIG. 48(a), it was revealed that CD4 positive T cells were not activated even when they were cultured alone.
[0484] Furthermore, as shown in FIG. 48(b), when CD4-positive T cells derived from healthy volunteer #21 were co-cultured with 585A1 iPS cells, 45.6% of the CD4-positive T cells were activated and became CFSE-negative.
[0485] Furthermore, as shown in Figure 48(c), when CD4-positive T cells derived from healthy volunteer #21 were co-cultured with 585A1-C7 remaining cells, 49.2% of the CD4-positive T cells were activated and became CFSE-negative.
[0486] Furthermore, as shown in Figure 48(d), it was revealed that the CD4-positive T cells derived from healthy volunteer #21 were not activated even when co-cultured with cells (clone #3-1-3) in which the CIITA gene of 585A1-C7 residual cells had been knocked out.
[0487] [Experimental Example 41] (Activation test of CD4 positive T cells, CD8 positive T cells and NK cells) Peripheral blood mononuclear cells (PBMC, type "LP_329", CTL) were stained with CFSE (Cayman Chemical). Table 57 below shows the HLA haplotypes of PBMC (type "LP_329", CTL).
[0488] [Table 57]
[0489] Next, the above PBMCs were mixed and co-cultured for one week with (1) 585A1 iPS cells, (2) clone #3-1 (hereinafter sometimes referred to as "585A1-C7 remaining cells") prepared in Experimental Example 13 in which the A*24:02 allele, B*07:02 allele, B*52:01 allele, and C*12:02 allele of 585A1 iPS cells were knocked out, (3) cells (clone #3-1-3) prepared in Experimental Example 39 in which the CIITA gene of 585A1-C7 remaining cells was knocked out, (4) EB-derived blood cell-like cells differentiated from each of the cells of clone #3-1-6, and (5) K562 cells known not to express HLA antigens. For comparison, (6) a group in which only the above PBMCs were cultured alone for one week was also prepared.
[0490] After co-culture, flow cytometry analysis was performed to examine CFSE fluorescence. Figure 49 (a) to (c) are graphs showing the results of flow cytometry. In Figure 49 (a) to (c), "Mock" shows the result of culturing only PBMC alone as described above in (6), "585A1-WT" shows the result of EB-derived blood cell-like cells induced to differentiate from the 585A1 iPS cells as described above in (1), "585A1-C7#3-1" shows the result of EB-derived blood cell-like cells induced to differentiate from the 585A1-C7 remaining cells as described above in (2), and "585A1-C7+CIITA - #3-1-3" indicates the result of EB-derived hemocyte-like cells induced to differentiate from the cells (clone #3-1-3) in which the CIITA gene of the 585A1-C7 remaining cells in (3) above was knocked out, and "585A1-C7+CIITA - "#3-1-6" indicates the results for EB-derived hemocyte-like cells induced to differentiate from cells (clone #3-1-6) in which the CIITA gene of the 585A1-C7 remaining cells described above (4) was knocked out, and "K562" indicates the results for the K562 cells described above (5).
[0491] As a result, as shown in Figure 49(a), it was revealed that CD8 positive T cells reacted to EB-derived hemocyte-like cells induced to differentiate from 585A1 iPS cells, and 51.0% of CD8 positive T cells were activated and became CFSE negative. In contrast, it was revealed that only 2% or less of CD8 positive T cells were activated when co-cultured with cells other than EB-derived hemocyte-like cells induced to differentiate from 585A1 iPS cells.
[0492] Furthermore, as shown in Figure 49(b), it was revealed that CD4 positive T cells reacted with EB-derived hemocyte-like cells induced to differentiate from 585A1 iPS cells and EB-derived hemocyte-like cells induced to differentiate from 585A1-C7 remaining cells, and 49.2% and 26.7% of CD4 positive T cells were activated and became CFSE negative, respectively. In contrast, it was revealed that only 2% or less of CD4 positive T cells were activated even when co-cultured with other cells.
[0493] In addition, as shown in Figure 49(c), it was revealed that NK cells reacted with K562 cells, and 79.2% of the NK cells were activated and became CFSE negative. In contrast, it was revealed that only 7% or less of the NK cells were activated when co-cultured with other cells.
[0494] [Experimental Example 42] (Creation of HLA-C7-retaining CIITA-deficient iPS cells) The HLA-A allele, HLA-B allele, and CIITA allele were knocked out from iPS stock cells (Ff-Xt-28s05 iPS cells) that have the third highest HLA allele frequency in Japanese people. The knockout was performed by one-stage and two-stage genome editing, respectively. Table 58 below shows the HLA haplotype of Ff-Xt-28s05 iPS cells.
[0495] [Table 58]
[0496] Figures 50(a) to (c) are diagrams explaining the procedure of this experimental example. Figure 50(a) is a diagram explaining the procedure for knocking out HLA-A allele, HLA-B allele, and CIITA allele in one step. Figures 50(b) and (c) are diagrams explaining the procedure for knocking out HLA-A allele, HLA-B allele, and CIITA allele in two steps.
[0497] In the one-step knockout, first, as shown in FIG. 50(a), Ff-Xt-28s05 iPS cells were transfected with A-ex3-g1 (target nucleotide sequence shown in SEQ ID NO: 55), which is an sgRNA capable of targeting the HLA-A allele, B-ex2-g1 (target nucleotide sequence shown in SEQ ID NO: 53), which is an sgRNA capable of targeting the HLA-B allele, and CIITA-ex3g5 (target nucleotide sequence shown in SEQ ID NO: 8017), which is an sgRNA capable of targeting the CIITA allele, and purified Cas9 protein. Transfection was performed using a commercially available kit (product name "4D-Nucleofector", model number "V4XP-4032", Lonza).
[0498] Next, the iPS cells were stimulated with 50 ng / mL IFN-γ for 48 hours, and flow cytometry analysis was performed to examine the expression of HLA-A24 antigen and HLA-B7 antigen. Figure 51(a) is a graph showing the results of flow cytometry. In Figure 51(a), "No stain" indicates the analysis result of iPS cells that were not stained with an antibody, "No TF" indicates the analysis result of iPS cells that were not introduced with sgRNA, "HLA-A-ex3g1" indicates the result of introducing A-ex3-g1 (target base sequence shown in SEQ ID NO: 55), "HLA-B-ex2g1" indicates the result of introducing B-ex2-g1 (target base sequence shown in SEQ ID NO: 53), and CIITA-ex3g5 (target base sequence shown in SEQ ID NO: 8017) indicates the result of introducing CIITA-ex3g5.
[0499] Next, the cell population negative for both HLA-A24 antigen and HLA-B7 antigen was sorted and collected to obtain 15 subclones. Next, the nucleotide sequences of the HLA-A24 allele, HLA-B7 allele, and CIITA allele of the genome of each subclone were analyzed. Figure 51(b) shows the nucleotide mutation pattern of each subclone. In Figure 51(b), "Clone ID" indicates the name of the subclone, "WT" indicates that the nucleotide sequence was of the wild type, "-" indicates that the subclone had a deletion mutation, "+" indicates that the subclone had an insertion mutation, and "ND" indicates that the nucleotide sequence was not determined. In addition, "ABTo" in the subclone name means that the HLA-A allele, HLA-B allele, and CIITA allele were knocked out.
[0500] As a result, as shown in Figure 51(b), clones #1, #2, #3, #6, #13, and #15 were obtained in which insertion deletion mutations (Indel mutations) were detected in all of the HLA-A allele, HLA-B allele, and CIITA allele.
[0501] In the two-step knockout, first, as shown in FIG. 50(b), Ff-Xt-28s05 iPS cells were transfected with A-ex3-g1 (target nucleotide sequence shown in SEQ ID NO: 55), which is an sgRNA capable of targeting HLA-A alleles, B-ex2-g1 (target nucleotide sequence shown in SEQ ID NO: 53), which is an sgRNA capable of targeting HLA-B alleles, and purified Cas9 protein to obtain 17 subclones. Transfection was performed using a commercially available kit (product name "4D-Nucleofector", model number "V4XP-4032", Lonza).
[0502] Next, the genomic base sequences of the HLA-A24 allele and HLA-B7 allele of each subclone were analyzed. Figure 52(a) shows the base mutation pattern of each subclone. In Figure 52(a), "Clone ID" indicates the subclone name, "WT" indicates that the base sequence was of the wild type, "-" indicates that the subclone had a deletion mutation, "+" indicates that the subclone had an insertion mutation, and "Mut." indicates that the subclone had a substitution mutation. In addition, "ABo" in the subclone name means that the HLA-A allele and the HLA-B allele were knocked out.
[0503] As a result, as shown in Figure 52(a), clone #14 was obtained in which an insertion deletion mutation (Indel mutation) was detected in both the HLA-A allele and the HLA-B allele.
[0504] Next, as shown in Figure 50(c), the obtained clone #14 was transfected with CIITA-ex3g5 (the target nucleotide sequence is shown in SEQ ID NO: 8017), which is an sgRNA capable of targeting the CIITA allele, and purified Cas9 protein to obtain 12 subclones. Transfection was performed using a commercially available kit (product name "4D-Nucleofector", model number "V4XP-4032", Lonza).
[0505] Next, the nucleotide sequence of the CIITA allele of the genome of each subclone was analyzed. Figure 52(b) shows the nucleotide mutation pattern of each subclone. In Figure 52(b), "Clone ID" indicates the subclone name, "WT" indicates that the nucleotide sequence was of the wild type, "-" indicates that it had a deletion mutation, "+" indicates that it had an insertion mutation, and "ND" indicates that the nucleotide sequence was not determined. In addition, "ABo_To" in the subclone name means that the HLA-A allele and HLA-B allele were knocked out and subcloned once, and then the CIITA allele was knocked out.
[0506] As a result, as shown in FIG. 52(b), clones #14-3, #14-4, #14-6, and #14-12 were obtained in which an insertion-deletion mutation (Indel mutation) resulting in a frameshift mutation was detected in both alleles of CIITA.
[0507] Figure 53 is a table showing the allele frequencies of HLC-C alleles in various races. In Figure 53, "JPN" indicates Japanese, "EUR" indicates European American, "AFA" indicates African American, "API" indicates Asian, and "HIS" indicates Hispanic. "Allele frequency" indicates the frequency (%) of the allele in each race, and "rank" indicates the order of frequency from highest to lowest.
[0508] As shown in Figure 53, by producing 12 types of cells, namely HLA-C*01:02, HLA-C*02:02, HLA-C*03:03, HLA-C*03:04, HLA-C*04:01, HLA-C*05:01, HLA-C*06:02, HLA-C*07:01, HLA-C*07:02, HLA-C*08:01, HLA-C*12:02, and HLA-C*16:01, it is possible to cover more than 93% of the population in any of the above races.
[0509] That is, cells lacking HLA-A and HLA-B alleles and having any of the above 12 types of HLA-C alleles, or cells lacking HLA-A, HLA-B and CIITA alleles and having any of the above 12 types of HLA-C alleles, are very useful as cells for cell therapy or regenerative medicine. Here, the cells are not particularly limited as long as they are cells used in cell therapy, and may be pluripotent stem cells or differentiated cells. Specifically, they may be, for example, iPS cells, T cells, hematopoietic stem cells, mesenchymal stem cells, etc.
[0510] [Experimental Example 43] (Creation of B2M knockout iPS cells 3) The B2M allele was knocked out from the iPS stock cells (Ff-Xt-28s05 iPS cells) used in Experimental Example 41.
[0511] Ff-Xt-28s05 iPS cells were transfected with B2M-g2 (target nucleotide sequence shown in SEQ ID NO: 60), an sgRNA capable of targeting the B2M allele, and purified Cas9 protein to obtain five subclones. Transfection was performed using a commercially available kit (product name "4D-Nucleofector", model number "V4XP-4032", Lonza).
[0512] Next, the nucleotide sequence of the B2M allele of the genome of each subclone was analyzed. Figure 54 shows the nucleotide mutation pattern of each subclone. In Figure 54, "Clone ID" indicates the subclone name, "WT" indicates that the nucleotide sequence was of the wild type, "-" indicates that the subclone had a deletion mutation, and "+" indicates that the subclone had an insertion mutation. In addition, "Mo" in the subclone name means that the B2M allele was knocked out.
[0513] As a result, as shown in FIG. 54, clones #1 and #3 in which a frameshift mutation occurred in the B2M allele were obtained.
[0514] [Experimental Example 44] (Generation of B2M and CIITA knockout iPS cells) The B2M allele and the CIITA allele were simultaneously knocked out from the iPS stock cells (Ff-Xt-28s05 iPS cells) used in Experimental Example 41.
[0515] Ff-Xt-28s05 iPS cells were transfected with B2M-g2 (target nucleotide sequence shown in SEQ ID NO: 60), an sgRNA capable of targeting the B2M allele, CIITA-ex3g5 (target nucleotide sequence shown in SEQ ID NO: 8017), an sgRNA capable of targeting the CIITA allele, and purified Cas9 protein to obtain 19 subclones. Transfection was performed using a commercially available kit (product name "4D-Nucleofector", model number "V4XP-4032", Lonza).
[0516] Next, the nucleotide sequences of the B2M allele and CIITA allele of the genome of each subclone were analyzed. Figure 55 shows the nucleotide mutation pattern of each subclone. In Figure 55, "Clone ID" indicates the subclone name, "WT" indicates that the nucleotide sequence was of the wild type, "-" indicates that the subclone had a deletion mutation, and "+" indicates that the subclone had an insertion mutation. In addition, "MTo" in the subclone name means that the B2M allele and the CIITA allele were knocked out in one step.
[0517] As a result, as shown in FIG. 55, clone #8 was obtained in which frameshift mutations occurred in both the B2M allele and the CIITA allele.
[0518] In addition, it was revealed that only one of the B2M alleles was knocked out, and both of the CIITA alleles were knocked out in clone #2. Therefore, clone #2 was obtained as a cell line in which essentially only the CIITA allele was knocked out.
[0519] [Experimental Example 45] (Examination of HLA protein expression in B2M and CIITA knockout iPS cells) The expression of HLA-ABC proteins in Ff-Xt-28s05-MTo#2 iPS cells prepared in Experimental Example 44 was examined.
[0520] First, Ff-Xt-28s05-MTo#2 iPS cells were stimulated with 50 ng / mL IFN-γ for 48 hours, then stained with anti-HLA-ABC antibody (product number: 311418, BIOLEGEND) and subjected to flow cytometry analysis to examine the expression of HLA-A protein, HLA-B protein, and HLA-C protein.
[0521] Figures 56(a) and (b) are graphs showing the results of flow cytometry. In Figure 56(a), "No stain" indicates the analysis result of iPS cells that were not stained with an antibody. In Figure 56(b), "Ff-Xt-28s05-MTo#2" indicates the analysis result of Ff-Xt-28s05-MTo#2 iPS cells.
[0522] As a result, it was revealed that Ff-Xt-28s05-MTo#2 iPS cells maintained the ability to express HLA-A protein, HLA-B protein, and HLA-C protein.
[0523] [Experimental Example 46] (Creation of B2M knockout iPS cells 4) 585A1 iPS cells were transfected with a plasmid vector expressing Cas9 and a B2M-specific sgRNA. The sgRNA used was B2M-g2 (the target nucleotide sequence is shown in SEQ ID NO: 60).
[0524] Next, cells stimulated with 50 ng / mL IFN-γ for 48 hours were stained with anti-HLA-ABC antibody and subjected to flow cytometry analysis.
[0525] Figure 57 is a graph showing the results of flow cytometry. In Figure 57, "No stain" indicates the analysis result of iPS cells that were not stained with an antibody, "No TF" indicates the analysis result of iPS cells that were not introduced with sgRNA, and "B2M-g2" indicates the analysis result of iPS cells in which this sgRNA was introduced to knock out the B2M allele.
[0526] As a result, the percentage of the cell population that was negative for all of the HLA-A protein, HLA-B protein, and HLA-C protein was 27.0%. Next, the cell population that was negative for all of the HLA-A, HLA-B, and HLA-C obtained by the introduction of B2M-g2 sgRNA was collected by sorting. No subcloning was performed here.
[0527] [Experimental Example 47] (HLA allele-specific knockout 10) Cells were prepared by knocking out the HLA-A allele, HLA-B allele, and HLA-C allele of 585A1 iPS cells. Specifically, the cells (clone #3) prepared in Experimental Example 13 in which the A*24:02 allele, B*07:02 allele, and B*52:01 allele of 585A1 iPS cells were knocked out were transfected with purified Cas9 protein, sgRNA specific for the C*07:02 allele, and sgRNA specific for the C*12:02 allele.
[0528] C0702-ex3-g3 (target base sequence shown in SEQ ID NO: 49) was used as the C*07:02 allele-specific sgRNA. C1202-ex3-g1 (target base sequence shown in SEQ ID NO: 50) was used as the C*12:02 allele-specific sgRNA. A commercially available kit (product name "4D-Nucleofector", model number "V4XP-4032", Lonza) was used for transfection.
[0529] Subcloning was then performed to obtain six subclones, and genomic DNA was extracted from each subclone. The base sequences of the HLA-C*07:02 and HLA-C*12:02 alleles were then analyzed by Sanger sequencing.
[0530] Figure 58 shows the nucleotide mutation patterns of each of the recovered clones. In Figure 58, "Clone ID" indicates the subclone name, "HLA-C07" indicates the HLA-C*07:02 allele, "HLA-C12" indicates the HLA-C*12:02 allele, "WT" indicates that the nucleotide sequence was wild type, "-" indicates that the clone had a deletion mutation, and "+" indicates that the clone had an insertion mutation. As a result, it was confirmed that both alleles of HLA-C were knocked out in clones #3-4, #3-5, #3-6, and #3-7.
[0531] [Experimental Example 48] (HLA allele-specific knockout 11) The 585A1 iPS cells (clone #3) prepared in Experimental Example 13 in which the A*24:02 allele, B*07:02 allele, and B*52:01 allele were knocked out were transfected with purified Cas9 protein and sgRNA specific for the C*07:02 allele.
[0532] C0702-ex3-g3 (target nucleotide sequence shown in SEQ ID NO: 49) was used as the C*07:02 allele-specific sgRNA. A commercially available kit (product name "4D-Nucleofector", model number "V4XP-4032", Lonza) was used for transfection.
[0533] Subcloning was then performed to obtain six subclones, and genomic DNA was extracted from each subclone. The base sequences of the HLA-C*07:02 and HLA-C*12:02 alleles were then analyzed by Sanger sequencing.
[0534] Figure 59 shows the nucleotide mutation patterns of each of the recovered clones. In Figure 59, "Clone ID" indicates the subclone name, "HLA-C07" indicates the HLA-C*07:02 allele, "HLA-C12" indicates the HLA-C*12:02 allele, "WT" indicates a wild-type nucleotide sequence, and "+" indicates that an insertion mutation was present. As a result, clones #3-1, #3-2, #3-3, #3-5, and #3-6 were confirmed to be clones in which the HLA-C*07:02 allele was knocked out and only the HLA-C*12:02 allele remained.
[0535] As described above with reference to Figure 53, by preparing 12 types of cells, namely HLA-C*01:02, HLA-C*02:02, HLA-C*03:03, HLA-C*03:04, HLA-C*04:01, HLA-C*05:01, HLA-C*06:02, HLA-C*07:01, HLA-C*07:02, HLA-C*08:01, HLA-C*12:02, and HLA-C*16:01, it is possible to cover 93% or more of the population in any of the following races: Japanese, European Americans, African Americans, Asians, and Hispanics.
[0536] The cells prepared in this experimental example can be used as one of these 12 types of cells.
[0537] [Experimental Example 49] (HLA allele-specific knockout 12) Cells (clone #4) in which the A*01:01 allele, A*24:02 allele, B*07:02 allele, and B*37:01 allele of 604B1 iPS cells prepared in Experimental Example 14 had been knocked out were transfected with purified Cas9 protein and sgRNA specific for the C*07:02 allele.
[0538] C0702-ex3-g3 (target nucleotide sequence shown in SEQ ID NO: 49) was used as the C*07:02 allele-specific sgRNA. A commercially available kit (product name "4D-Nucleofector", model number "V4XP-4032", Lonza) was used for transfection.
[0539] Subcloning was then performed to obtain 11 subclones, and genomic DNA was extracted from each subclone. The base sequences of the HLA-C*06:02 and HLA-C*12:02 alleles were then analyzed by Sanger sequencing.
[0540] Figure 60 shows the nucleotide mutation patterns of each of the recovered clones. In Figure 60, "Clone ID" indicates the subclone name, "HLA-C06" indicates the HLA-C*06:02 allele, "HLA-C07" indicates the HLA-C*07:02 allele, "WT" indicates that the nucleotide sequence was wild type, "-" indicates that the clone had an insertion mutation, and "+" indicates that the clone had an insertion mutation. As a result, clones #4-2, #4-6, #4-10, and #4-11 were confirmed to be clones in which the HLA-C*07:02 allele was knocked out and only the HLA-C*06:02 allele remained.
[0541] As described above with reference to Figure 53, by preparing 12 types of cells, namely HLA-C*01:02, HLA-C*02:02, HLA-C*03:03, HLA-C*03:04, HLA-C*04:01, HLA-C*05:01, HLA-C*06:02, HLA-C*07:01, HLA-C*07:02, HLA-C*08:01, HLA-C*12:02, and HLA-C*16:01, it is possible to cover 93% or more of the population in any of the following races: Japanese, European Americans, African Americans, Asians, and Hispanics.
[0542] The cells prepared in this experimental example can be used as one of these 12 types of cells. [Industrial Applicability]
[0543] According to the present invention, a technique for producing low antigenic cells with reduced rejection reactions when allogeneically transplanted into a recipient can be provided.
Claims
1. A cell that does not express HLA-A protein and HLA-B protein, but expresses at least one endogenous HLA-C protein, in which at least one allele selected from a Class II Major Histocompatibility Complex Transactivator (CIITA) allele, a Regulatory Factor X5 (RFX5) allele, a Regulatory Factor X Associated Protein (RFXAP) allele, and a Regulatory Factor X Associated Ankyrin Containing Protein (RFXANK) allele is disrupted or modified.
2. The cell of claim 1, wherein the HLA-A allele and the HLA-B allele are disrupted.
3. The cell according to claim 1 or 2, which is a pluripotent stem cell.
4. A method for producing the cell according to any one of claims 1 to 3, comprising a step of destroying HLA-A alleles and HLA-B alleles of a donor cell by genome editing.
5. The method of claim 4, wherein the genome editing is performed by introducing a sequence-specific DNA cleavage enzyme into the donor cell.
6. The method of claim 5, wherein the sequence-specific DNA cleaving enzyme is CRISPR-Cas, and the genome editing is performed by introducing gRNA and CRISPR-Cas into the donor cell.
7. The method according to any one of claims 4 to 6, wherein the donor cells are pluripotent stem cells.
8. The gRNA is A gRNA having a target base sequence that is mapped to only one target HLA haplotype when mapped to base sequence data of genomic DNA of all HLA haplotypes and is not mapped to base sequence data of all genomic DNA other than HLA alleles, wherein the target base sequence is a gRNA consisting of a base sequence set forth in any one of SEQ ID NOs: 3, 4, 7, 45 to 52, or a base sequence in which one or several bases have been deleted, substituted or added at the 5' end of the base sequence set forth in any one of SEQ ID NOs: 3, 4, 7, 45 to 52, or The method for producing a gRNA according to claim 6, wherein the gRNA has as its target base sequence a base sequence that is mapped to two or more target HLA haplotypes when mapped against base sequence data of genomic DNA of all HLA haplotypes and is not mapped when mapped against base sequence data of all genomic DNA other than HLA alleles, and the target base sequence is a gRNA consisting of a base sequence set forth in any one of SEQ ID NOs: 53 to 55, or a base sequence in which one or several bases have been deleted, substituted or added at the 5' end of the base sequence set forth in any one of SEQ ID NOs: 53 to 55.
Citation Information
Patent Citations
Methods and Compositions for Modifying HLA
JP2016513460A
Immocompatible cells produced by nuclease-mediated editing of genes encoding HLA
JP2017523813A
Beta-2 microglobulin-deficient cells
WO2012145384A1
Universal donor stem cells and related methods
WO2016183041A2
Crispr / CAS-related methods and compositions for improving transplantation
WO2016201047A1
